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Lots of things are mysteries.
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SUMMARY
Pharmacoepidemiology enables researchers to assess the effects of drugs on
outcomes, such as diseases, in large study populations. Furthermore, pharma-
coepidemiology is gaining importance in the premarketing phase of the drug
development process to provide information on the natural history of the dis-
ease the respective drug is being tested for.
Gout is a common, excruciatingly painful, long-known and widely spread
inflammatory arthritis characterized by increased serum uric acid levels, and
uric acid crystals in the joints (typically in the metatarsophalangeal joint,
called podagra). Even though the disease has been long-known and affects
about 1.4% to 2.5% of the United Kingdom (UK) population, evidence on
many risk factors is lacking. Studies that closely describe the affected popu-
lation and strengthen existing evidence on risk factors such as drug use are
needed to improve treatment and care of affected patients.
The aim of this thesis was to increase the knowledge of gout by providing
new information and complementing existing data, and by precisely describing
the epidemiology of gout and demographic characteristics, comorbidities, and
comedication of the affected population. Furthermore, the goal was to assess
the impact of long-known and accepted risk factors in a population-based set-
ting.
The gout project consisted of an epidemiological cohort study, a nested
case-control study, and three case-control studies, using data from the Clin-
ical Practice Research Datalink (CPRD). The CPRD is a UK-based general
practitioner database containing primary-care records directly entered by gen-
eral practitioners who do not have any study hypothesis in mind when they
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record the data. The CPRD population is representative of the UK population
in terms of age, sex, geographic distribution, and annual turnover rate. The
CPRD is a very useful tool to conduct pharmacoepidemiological research due
to its large size, the population-based character of the data, and the opportu-
nity for researchers to gain access to original medical records. However, data
on some important confounders such as dietary habits are missing.
All case-control populations of the different gout projects were matched on
age, sex, general practice, index date, and history on the CPRD. The overall
incidence rate of diagnosed gout in the UK per 10,000 person-years (PYs) was
18.0 (95% CI 17.9-18.1), 29.0 (95% CI 28.8-29.2) in men, and 8.6 (95% CI
8.5-8.8) in women; we further stratified by age, calendar time, region, and sea-
sonality. The nested case-control part of the first project described the study
population in terms of demographic characteristics, comorbidities, and comed-
ication. The second project assessed the association between different diuretic
drug classes and incident gout. Current use of loop diuretics, thiazide diuret-
ics, and thiazide-like diuretics was associated with a substantially increased
risk of incident gout. In the third project, the association between different
antidiabetic drug classes, diabetes duration, and diabetes severity and the risk
of incident gout was investigated. Increasing glycosylated haemoglobin (A1C)
levels were associated with a markedly decreased risk of incident gout in pa-
tients with type 2 diabetes mellitus. Neither use of insulin, metformin, nor
sulfonylureas was associated with an altered risk of incident gout. The fourth
project assessed the association of hormone replacement therapy with gout,
and the effect of timing, duration, and route of administration. Current use of
oral opposed oestrogens, but not unopposed oestrogens, was associated with a
decreased risk of incident gout in patients without renal failure and was more
pronounced in patients with hypertension. The observed risk decrease for gout
in users of opposed oestrogens may be explained by the progesterone rather
than the oestrogen component.
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In summary, these large observational studies of this thesis analysed ex-
isting hypotheses and contributed to the evidence of different risk factors for
gout such as diuretic drug classes, antidiabetic drugs, diabetes duration and
severity, and hormone replacement therapy. Furthermore, several interesting
ideas developed in the context of this thesis might be studied in association
with gout within the CPRD in near future, to further increase evidence on risk
factors associated with the disease, and to improve patient care.
iii
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Part I
INTRODUCTION

1. PHARMACOEPIDEMIOLOGY
1.1 Definition
Pharmacoepidemiology is the study of the use of and the effects of drugs
in large numbers of people (1).
1.2 Development
After the thalidomide disaster, where children of mothers who used this
drug during pregnancy were born with limb deformations, the awareness of
serious adverse drug effects increased rapidly and in the 1960s several devel-
opments have prompted the beginning of the science Pharmacoepidemiology
(1). Post-marketing drug surveillance was first initiated with spontaneous re-
porting systems in the United States and Europe in which suspected adverse
drug events were captured and centred. The focus lay on the assessment of
drug effects that were difficult to capture in preclinical randomized controlled
trials due to limited numbers of participants, rather short duration, and non
representative patient populations (1). With the composition of databases the
quantitative assessment of drug hazards in post-marketing drug surveillance
became feasible.
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2. THE DATABASE: CLINICAL PRACTICE RESEARCH DATALINK
Databases are a very important source for pharmacoepidemiological stud-
ies. One of the largest and most detailed computerised databases is the Clinical
Practice Research Datalink (CPRD).
2.1 History of the CPRD
The CPRD contains population-based data from the United Kingdom (UK)
and was first established in 1987 (2, 3). Back in the 1980s, a company de-
veloped a computer system called Value Added Medical Products (VAMP)
which enabled enrolled general practitioners to record electronically their pa-
tient information (2, 4). The general practitioners who participated provided
anonymised data to the centralized database and were trained in data quality
(2, 4, 5). The VAMP database was donated to the UK department of Health in
1994 and renamed into General Practice Research Database (GPRD) (5). In
April 2012 the database was linked to several datasets and again was renamed
into the Clinical Practice Research Datalink (CPRD). The Boston Collabora-
tive Drug Surveillance Program (BCDSP) conducted a broad range of studies
to evaluate the quality and completeness of the recorded data for research pur-
poses, especially drug safety studies (2, 4, 5). Since 1991 most practices have
been providing data of required quality and completeness for pharmacoepi-
demiological studies (6). However, for a limited number of practices data have
been available since 1987 (2, 5). Since 1994 the CPRD has belonged to the
UK department of Health and is currently managed by the UK Medicines and
Healthcare products Regulatory Agency (MHRA) (6). To date, the CPRD
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has been validated extensively and the individuals enrolled in the database
are representative of the UK population with regard to age, sex, geographic
distribution, and annual turnover rate (6–10).
2.2 Data in the CPRD
All information available from the CPRD is anonymised for research pur-
poses (2, 4–6). The general practitioner provides extensive information on
medical symptoms and diagnoses using Read medical codes, therapy (medica-
tion prescriptions, vaccines, medical devices), patient demographics (including
age and sex), lifestyle factors (including height, weight, smoking status, and al-
cohol consumption), laboratory tests, pathology results, treatment outcomes,
events leading to withdrawal of a treatment, patient registration, practice,
and consultation details (6). In addition, information on hospital discharge
letters, outpatient diagnoses, and referrals to second care or specialists are
also provided, since within the National Health Service (NHS) all consultants
are required to forward the information to the general practitioner who rep-
resents the primary care giver (6). The database has been described in detail
(3, 11) and has been validated extensively (2, 4, 5, 9, 10, 12). A systematic
review supported a high validity of recorded diagnoses in the CPRD (13). To
date, the CPRD comprises more than 40 million patient-years from more than
600 participating practices (9, 14).
2.2.1 Read codes
Within the CPRD, diagnoses and symptoms are coded with Read medical
codes (15). Read codes are a coded thesaurus of clinical terms which facilitate
efficient modern electronic communication and support patient records, public
health and activity reporting, payments, audit, research, and the automation
of repetitive manual tasks (15, 16). Read codes are the standard clinical termi-
nology system used in general practice in the UK (16, 17). It supports detailed
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clinical encoding of multiple patient phenomena, such as clinical signs, symp-
toms and observations, laboratory tests and results, diagnoses, and diagnostic,
therapeutic or surgical procedures performed (15, 17).
2.2.2 Prescribing codes
Until recently the prescribing codes were based on the Multilex drug ter-
minology which included clinical and commercial information on more than
75,000 pharmaceutical products and packs and provides active clinical decision
support and referential medicines information for all healthcare professionals.
The Multilex drug knowledge base is widely used throughout the UK and is
integrated into clinical systems across the whole healthcare community. In
2013 the CPRD introduced a new coding system called Gemscript (18).
2.2.3 Hospital Episode Statistics
The Hospital Episode Statistics (HES) contains details on all admissions,
outpatient appointments, and accident and emergency attendances at NHS
hospitals in England. It is a records-based system that covers all NHS trusts
in England, including acute hospitals, primary care trusts, and mental health
trusts. HES data provide several benefits for epidemiological studies, for ex-
ample, it enables the assessment of effective delivery of care (19).
2.3 Gout diagnosis within the CPRD
Many studies suggest high validity of data within the CPRD in general
(2, 4, 5, 10, 12). Additionally, a systematic review suggested a high validity
of recorded diagnoses stating that on average 89% of recorded diagnoses were
confirmed (13).
The gout diagnosis was evaluated through profile reviewing and was re-
ported to be highly valid in 1997 (20). Other studies used similar patient
definitions for the diagnosis of gout as those used in this thesis (7, 21–23).
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2.4 Ethical approval
Study protocols have to be approved by the Independent Scientific Advisory
Committee (ISAC) for Medicines and Healthcare products Regulatory Agency
(MHRA) database research.
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3. EPIDEMIOLOGIC STUDY DESIGNS
Clinical research is either experimental or observational, based on whether
the investigator assigns the exposures or not (24, 25). Observational studies
can be either descriptive or analytical (24). Descriptive studies describe the
occurrence of outcome while analytical studies measure the association be-
tween exposure and outcome but only analytical studies include a comparison
or control group (24, 25). Pharmacoepidemiology aims at describing the asso-
ciation between exposures and outcomes. Hypotheses can be tested to some
extent, but no causal relationship can be proven (26, 27).
3.1 Descriptive studies
Descriptive studies either deal with individuals (case reports, case-series
reports, cross-sectional studies, and surveillance studies) or relate to popula-
tions (ecological correlational studies), and describe the occurrence of outcome
(28). Even if descriptive studies do not have a comparison group and therefore
cannot measure association, they can be used to generate hypotheses that can
be tested in analytical studies (28).
3.2 Cohort studies
Cohort studies track groups forward in time from exposure to outcome and
can be carried out prospectively or retrospectively (24, 29). A cohort study is
the best way to identify incidence and natural history of a disease and can be
used to examine multiple outcomes after a single exposure (29).
Confounding factors, which can lead to spurious findings, need to be mea-
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sured and controlled for (29). Loss to follow-up, which occurs when patients
who at one point in time were actively participating, e.g. in a clinical research
trial, have become lost either by error in a computer tracking system or by
being unreachable in the point of follow-up in the trial, is a challenge (29).
The measure of association is the relative risk (29).
For this thesis, a cohort design was used to calculate incidence rates (IRs)
with 95% confidence intervals (CIs) of incident gout within the overall CPRD
population.
3.3 Case-control studies
Case-control studies include cases with the outcome of interest, e.g. inci-
dent gout, and controls without the respective outcome (24, 30). In contrast
to cohort studies, case-control studies are carried out retrospectively (30).
To yield good validity of the data, some important points should be con-
sidered (24, 30): The researcher should define precise eligibility criteria for the
selection of a case. The same eligibility criteria should be applied for the selec-
tion of controls, except they are not allowed to have the outcome of interest.
Controls should be from the same population and the selection criteria should
be independent of exposure. Case-control status should be blinded and expo-
sure has to be assessed in the same way in cases and controls. Confounding
should be addressed either in designing the study, i.e. in matching controls to
cases, or in using analytical techniques.
Ideally, the only difference between cases and controls should be the out-
come status. Prevalence of an exposure is compared between the case and the
respective control and the measure of association is the odds ratio (30).
For this thesis, a case-control design was used to calculate odds ratios (ORs)
with 95% CIs of incident gout in association with use of diuretics, antidiabetic
drugs, diabetes duration and severity, and use of hormone replacement therapy.
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3.4 Nested case-control studies
A case-control study is nested when the study population stems from a well-
defined cohort, but almost any case-control study can be thought of as nested
within some source population (26, 31, 32). A nested case-control study is more
efficient if more information on exposure is needed than is readily available
from records and if it would be too expensive to seek this information for the
whole cohort (26).
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4. BIAS
An observed relation may be either true or caused by chance or by an
erroneous analysis (1). An error can either be at random or systematic; a
bias is generally any systematic error in an epidemiological study due to the
incorrect assessment of the association between an exposure and an effect or the
lack of internal validity (33). The most important biases are those related to
the definition and selection of the study population called selection bias, to the
data collection called information bias, or to the association between different
determinants of an effect in the population called confounding (33, 34). It is
important to consider the different types of biases, and the likely direction and
size of the resulting effect (1).
4.1 Selection bias
The term selection bias includes various biases, such as inappropriate se-
lection of controls in case-control studies, or informative censoring in cohort
studies (35, 36). A selection bias occurs when the study population is different
to the target population, therefore not representative (33). This bias can be
introduced at several stages, either by defining poor eligibility criteria, inac-
curate sampling frame, or unequal diagnostic procedures between the study
population and the target population (33).
A further bias is called healthy user bias where cases differ with regard to
their adherence to preventive treatments and those with a good compliance
may be systematically healthier (37, 38). In addition, prevalent user bias can
occur in cohort studies which compare prevalent users of a drug to non-users
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of the respective drug due to the fact that prevalent users have by definition
survived under treatment (39). Selection bias should be addressed at the stage
of study design by matching (33, 40).
4.2 Information bias
Information bias is related to the accuracy of information, arises during
data collection, and can be divided into random misclassification or non-
random misclassification. Non-random misclassification can be further divided
into recall bias or observer bias (26). The three main types of information bias
are misclassification bias, ecological fallacy, and regression to the mean (26).
4.3 Confounding
Confounding is a mixing of effects, meaning that the effect of the exposure is
mixed with the effect of another variable, leading to a bias (26). A confounder
must be associated with the disease, either as a cause or as a proxy for a cause,
but not as an effect of it. Additionally, it must be associated with the exposure
without being an effect of it (26). The effect of confounders can be reduced by
matching for some factors, such as age, gender, location of residence etc., or
by a random selection of cases and controls from a study population (25). In
the analysis, confounding can be controlled for by adjusting for the presence
or absence of multiple confounding factors (25).
A special occurrence of confounding is confounding by indication. It is
sometimes encountered in observational studies of drug effects because the
allocation of treatment is not randomized and the indication for treatment
may be related to the risk of future health outcomes (41). However, this bias
often occurs in studies of drugs that are not widely prescribed, if indication
for their use is narrow and not likely to be present in the comparison group
(41).
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4.4 Interaction
Interaction in epidemiology, also called effect modification or effect measure
modification, refers to the common situation in which a measure of effect
changes over values of some other variable (26). Calculation of stratum-specific
effects is necessary to show the influence of the effect modifier on the association
between the exposure and the outcome (42).
13

The Gout, caricature by James Gillray (1799)

Die bo¨se Gicht
Starker Schmerz in Hand und Bein,
la¨sst schließen auf das Zipperlein,
wenn die Zehe teuflisch sticht,
dann vergesse man es nicht:
zuviel an Fleisch, zuwenig Fisch
kommt in der Regel auf dem Tisch.
Ist man dem Weine zugetan,
oder A¨thanol und Ethylen
fa¨ngt das Spiel genauso an,
dann muss dich auch der Doktor seh’n.
Zuviel der Sa¨ure in dem Harn,
wird die Schmerzen nicht erspar’n,
lieber etwas leiser treten,
mit Alkohol und mit den Fetten,
kann eine Linderung bedeuten,
was manche Gichtler nicht bereuten.
von Franz Christian Ho¨rschla¨ger

5. GOUT
5.1 Definition
Gout is an acute, excruciatingly painful, inflammatory arthritis that oc-
curs suddenly with a maximal severity within 12 to 24 hours and resolves
spontaneously and completely, even without treatment, within a few days to
several weeks (43–45). Gout is a consequence of hyperuricaemia, an extracel-
lular elevation of uric acid levels, which is defined as urate levels >6.8 mg/dl
(≥360mmol/l) (45, 46); if saturation threshold is reached, uric acid can crys-
tallize, and the monosodium urate crystals, called tophi, can deposit in joints,
tendons, bone, cartilage, skin, surrounding tissues, and seldom in parenchy-
mal organs, with a chronic inflammatory response as a general tissue reaction
(45, 46). The solubility of monosodium urate depends on temperature and
falls rapidly with decreasing temperature (47). Most often a single joint is
involved, and it is called podagra, when acute gout involves the base of the
great toe, with a red, tender, hot, swollen metatarsophalangeal joint. Hyper-
uricaemia can occur by impaired renal excretion, overproduction of uric acid,
or by overconsumption of purine-rich foods that are metabolized to urate (48–
50). Even if hyperuricaemia is a necessary predisposing factor, its presence
does not always lead to the onset of gout (51–53).
The three stages in natural history of gout are acute gouty arthritis, inter-
critical gout, and chronic recurrent and tophaceous gout (54).
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5.2 History
Gout is one of the oldest known diseases and has first been identified by
the Egyptians. Hippocrates, an ancient Greek physician, referred to it as the
unwalkable disease in the fifth century (55). Some of Hippocrates aphorisms
are still more or less valuable today, as e.g.
”
a women does not take the gout,
unless her menses be stopped“or
”
in gouty affections, inflammation subsides
within 40 days“(55). Hippocrates noted the link between the disease and an
intemperate lifestyle, referring to podagra, as the arthritis of the rich or the
arthritis of kings, how it was called throughout history since in the past only
affluent people could afford such a lifestyle (55). Later, Galen, a prominent
Greek physician, surgeon and philosopher in the Roman empire, was the first
to describe gouty tophi, the crystallized monosodium urate deposits, and as-
sociated gout with debauchery and intemperance, and recognized a hereditary
trait that had previously been referred to by Seneca, a Roman philosopher and
statesman (55).
The Dominican monk Randolphus of Bocking was the first person to use
the word gout to describe podagra in the 13th century:
”
gutta quam podagram
vel artiticam vocant“ –
”
the gout that is called podagra or arthritis“(55). The
term gout is derived from the Latin word gutta which means drop. This was at
a time when current knowledge was the belief that an excess of one of the four
humours of Hippocratic medicine – which in equilibrium were thought to main-
tain health – would flow or drop into a joint causing pain and inflammation
(55).
Der Hencker und die Gicht
Der Hencker und die Gicht verschaffen gleiche Pein;
Nur er macht kleine lang, sie lange Leute klein.
von Friedrich von Logau
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5.3 Diagnosis and management
The diagnosis focuses on the fundamental pathophysiologic events defining
the clinical state with tissue deposition of urate crystals and the accompany-
ing inflammation and potentially destructive consequences. The visualization
of monosodium urate crystals by experienced examiners in a sample of fluid
aspirated from an affected joint or tophi is the gold standard for the diagnosis
of gout, but in daily practice it is sometimes impossible to perform (especially
in primary care); thus, the diagnosis is mostly based on clinical judgement,
including patient history, physical examination, appropriate laboratory tests,
and increasingly imaging studies (56, 57).
In 1963 the Rome criteria, in 1968 the New York criteria, and in 1977
the American Rheumatism Association diagnostic criteria (58) guidelines for
the diagnosis of acute gout were published (59). The American College of
Rheumatology formulated criteria in order to classify gout without identifica-
tion of monosodium urate (58). The criteria were not developed with reference
to monosodium urate crystals, nor were they tested properly afterwards against
this gold standard, and therefore have shown limited validity (56, 57). How-
ever, the criteria can provide support for a diagnosis or exclusion of gout, but
crystal identification should remain the gold standard (56, 57).
The most recent European criteria recommendations from the European
League Against Rheumatism Recommendations (EULAR) have been devel-
oped on clinical practice and the best available evidence in 2006 (59). Ten
key recommendations regarding clinical features of gout, biochemical exami-
nations, urate crystals, radiographs, risk factors, and comorbidities have been
evaluated (59). Furthermore, most recent guidelines by the British Society for
Rheumatology and British Health Professionals in Rheumatology (BSR/BHPR)
released in 2007 contain patient-focused, evidence-based recommendations for
the management of gout for primary care and hospital practice in the UK
(54).
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Differential diagnoses include septic arthritis, osteoarthritis, rheumatoid
arthritis, hemochromatosis, trauma, or calcium pyrophosphate deposition (pseu-
dogout).
5.4 Epidemiology
Gout is an inflammatory, painful arthritis with acute onset (60, 61) with
a reported prevalence in the UK population of about 1.4% between 1999 and
2005 (7, 46) and about 2.5% in 2012 (23). The incidence was reported to be
17.7 per 10,000 PYs in 2012 (23) and appears to be rising (62, 63).
Die Gicht
Die Gicht verbeut den Wein zu trincken,
Sonst mustu liegen oder hincken.
Mich du¨nckt, es sey ein groß Verdruß,
Wann u¨ber Maul regirt der Fuß.
von Friedrich von Logau
5.4.1 Risk factors
Hyperuricaemia is the most important risk factor for gout (43, 64). Increas-
ing age, male gender (7), obesity (65, 66), and alcohol intake, especially beer
and spirits (66, 67), are other important risk factors. In addition, high levels of
purine-rich food, fructose-containing sugars, dehydration, trauma or surgery,
ingestion of drugs affecting serum urate concentrations, e.g. allopurinol, urico-
suric agents, thiazide or loop diuretics, and low-dose acetylsalicylic acid may
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promote gouty attacks (48, 50, 66, 68). Furthermore, comorbidities such as
hypertension and cardiovascular diseases are associated with gout (7, 66, 69).
On the other hand, higher coffee consumption was associated with a lower risk
of gout (70, 71).
5.4.2 Gender differences
Gout has long been considered a male disease, while during the time of the
Roman Empire Seneca, a Roman Stoic philosopher, was the first to observe
that women suffered from gout only at older ages (55). Previous studies re-
ported gender differences, especially that women were older at onset of gouty
arthritis (43, 44, 72). Since today people grow older, gout has become increas-
ingly more frequent in women, particularly after menopause (73, 74).
In addition, women with gout have a higher prevalence of comorbidities
such as hypertension or renal insufficiency, and more frequently used diuretics
(44, 72). However, women with gout are less likely to drink alcohol, suffer
less often from podagra but more often have involvement of other joints such
as finger or ankle, have less frequent recurrent attacks, and receive different
treatment patterns compared to men (44, 72). Atypical locations may cause
a delay in the diagnosis in women due to unfamiliarity of physicians or due to
the severity of coexisting diseases (44).
5.4.3 Regional differences
The lifestyle in Western countries predisposes individuals to hyperuricaemia
and gout: an excess of dietary purines derived from meat, seafood, and beer
increases the incidence and prevalence of gout. Asian cultures relatively rarely
suffer from gout due to their nutrition based on rice and vegetables, which are
low in purines (48, 50). However, even within the UK some regional differ-
ences have been shown based on the assumption of differences in socioeconomic
status, lifestyle, and nutrition (75).
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5.4.4 Seasonal differences
Seasonal differences have been known for a long time. One of Hippocrates
aphorism was:
”
Gouty affections become active in spring and in autumn“(55).
In contrast, a study reported increased incidence during the summer period,
late April to mid-September (76).
5.5 Treatment
Treatment goals in an acute gout attack are to (54):
– Exclude a diagnosis of septic arthritis.
– Terminate the attack and improve symptoms as promptly as possible
using non-pharmacological and pharmacological treatments.
– Seek, assess, and control associated diseases, such as diabetes mellitus,
hypertension, hyperlipidaemia and cardiovascular disease.
Current guidelines by the British Society for Rheumatology and British
Health Professionals in Rheumatology (BSR/BHPR) (54) and the EULAR
(77), both relating to the management of gout in primary care, are similar
and propose non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, or
corticosteroid as initial treatment. After four to six weeks patients should be
reviewed and lifestyle factors, blood pressure, serum urate levels, renal func-
tion, and glucose should be assessed (54).
The current guidelines (54, 77) encourage urate-lowering therapy if pa-
tients had two or more attacks of acute gout, or have other risk factors that
would make further attacks likely. The initiation of urate-lowering therapy can
precipitate an acute gouty attack; therefore a prophylaxis is usually given to
prevent this complication. However, the urate-lowering therapy should not be
interrupted in patients on such therapy at the time of an acute attack (54, 77).
With effective therapies, progression of gout to the chronic tophaceous
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stage is now less frequent among the compliant patients with primary gout
and among most patients with secondary gout (54, 77). In general, treatments
for gout are well tolerated, although they are associated with the potential for
drug interaction which can be influenced by patient comorbidities and con-
comitant medication (78).
During the last decades advances in the understanding, causes and patho-
physiology of hyperuricaemia and gout have led to the development of effective
therapies (55). In addition, patients with renal impairment or continuing acute
gout attacks are now considered in the guideline (54). However, challenges re-
main in treating patients with renal impairment (78).
Artzney wider Gicht
Wer Gicht auffs Alter nicht wil leiden,
Der mag sich jung bald lassen schneiden.
von Friedrich von Logau
5.5.1 Diet
Purine-rich food has long been known to be a major risk factor for hyperuri-
caemia and gout, and the knowledge that gout could be controlled by lowering
the intake of purine-rich food have been long known (48, 50). However, dietary
restrictions or modifications as a means of controlling gout has so far largely
been neglected (55), even though, in the current British Society for Rheuma-
tology and British Health Professionals in Rheumatology (BSR/BHPR) guide-
line recommendations for diet, lifestyle modifications and non-pharmacological
modalities are included (54).
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5.5.2 Initial treatment of acute gouty attacks
Several classes of anti-inflammatory agents are effective for the treatment of
acute gout, including NSAIDs, colchicine, and systemic and intra-articular glu-
cocorticoids (77). Nowadays, NSAIDs with or without proton pump inhibitors
are the drugs of choice (43, 54). Furthermore, colchicine and (systemic) corti-
costeroids are recommended but used less frequently due to relative contraindi-
cations (54).
There is evidence that colchicine was used 2000 years ago, while its use
against gout has been reported for the first time in the 6th century (55). Since
Thomas Sydenham, an English physician who lived in the 17th century, rejected
all medications that were purgatives as being too toxic for use, colchicine was
not used for the treatment of gout for about 150 years. It was not until 250
years ago that it was rediscovered in 1763 (55). Colchicine has been long
known to cause dose-dependent gastrointestinal side effects, to have a narrow
therapeutic index, and to induce drug interactions (78).
A set of general principles is important in the effective management of acute
gout, regardless of the specific anti-inflammatory agent used (76): Treatment
should start as soon as possible after the beginning of the attack, preferably
within several hours of symptom onset. More rapid and complete resolution
of symptoms occurs the earlier the treatment is introduced. However, to reach
that, treatment should be initiated at the recommended dose of the chosen
anti-inflammatory agent. In addition, the therapy should be continued for the
duration of the attack, usually until a complete cessation within two to three
days is reached, but dosage can usually be reduced once a significant response
is achieved. Oral glucocorticoids are an exception, slightly slower tapering may
be needed to avoid a recurrent attack.
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5.5.3 Urate lowering therapy
Urate-lowering therapies are of no benefit for acute gout and should gen-
erally not be initiated during an acute attack (54, 77). However, patents who
already receive these agents should not discontinue the medication, as there is
no benefit from temporary discontinuation, and subsequent reintroduction of
the agent may predispose to another attack (54, 77). Therapeutic recommen-
dations for acute gout attacks in patients receiving urate-lowering therapy are
the same as those for patients without such a therapy (54, 77).
Uricosuric agents were first used at the end of the 19th century and enhance
the renal clearance of urate (79). Firstly, high doses of salicylates were used
to induce uricosuria and resolution of tophi (79). Salicylates have a bimodal
effect on urate excretion dependent on dosage: while low doses reduce urate
excretion, high doses (4-6g/day) are uricosuric (80). Even though salicylates
were effective, they were not used for long due to the toxicity and impracti-
cality of high-dose therapy, and were replaced by probenecid, sulfinpyrazone,
and benzbromarone (55, 81). In 2001 the antihypertensive agent losartan, an
angiotensin receptor blocker, and the lipid-lowering fibrate fenofibrate were
shown to have moderate uricosuric effects (82, 83). However, neither is tested
nor licenced for the treatment of gout or hyperuricaemia.
Allopurinol, which was the first xanthine oxidase inhibitor, is an important
advance in the treatment of hyperuricaemia and gout, and has become the most
frequently used uric acid lowering drug in clinical practice (54). Xanthine ox-
idase inhibitors act by inhibiting the synthesis of uric acid from hypoxanthine
and xanthine, are effective in reducing plasma and urinary urate levels, and
have been shown to even dissolve tophaceous deposits (84). The indication
of allopurinol is the reduction of urate formation where urate deposition has
occurred or is predictable (84).
Clinical trials have shown febuxostat, a novel selective inhibitor of xanthine
oxidase, to be very effective in lowering uric acid levels (78). Febuxostat is rec-
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ommended as an option for chronic hyperuricaemia in gout when allopurinol
is contraindicated or not tolerated (84).
Rasburicase catalyses the conversion of uric acid to allantoin, which is five
to ten times more water-soluble than uric acid and is easier for the kidneys to
excrete (85). However, rasburicase is much more expensive than conventional
therapy (85). Its indication within the UK is the treatment and prophylaxis
of acute hyperuricaemia in patients with haematological malignancy with a
high tumour burden and who are at risk of rapid tumour lysis or shrinkage at
initiation of chemotherapy (84).
5.5.4 Investigational therapy
Patients whose gouty flares are resistant to all above mentioned therapies
may benefit from the use of a biologic agent canakinumab, which is a human
monoclonal antibody, that inhibits the action of interleukin-1 beta, which is an
important mediator of gouty inflammation and a potential therapeutic target
in acute gout (77). This agent is under investigation for the treatment of acute
gout and is up to now only used in patients who did not respond to all other
available treatments and who suffer from frequent attacks (78).
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Part II
OBJECTIVES

6. AIMS OF THE THESIS
The aim of this thesis was to contribute newsworthy information on asso-
ciations with incident gout by using data from the well validated UK-based
primary-care database CPRD:
– The ambition of the first project was a sound analysis of incidence rates
stratified by age, gender, index year, region, and season. A secondary aim
was the thorough description of the demographic characteristics, comor-
bidities, comedication, and treatment pattern of the nested case-control
population.
– The purpose of the second project on diuretic drug use was to increase
the awareness of these drugs in association with the development of gout
and to clarify in more detail which diuretic drug classes are associated
with the disease.
– The aim of the third project was to clarify the impact of anti-diabetic
drugs, diabetes severity, and diabetes duration in type 2 diabetes mellitus
patients on the risk of incident gout.
– The objective of the fourth project was to assess the risk of developing
incident gout in association with use of hormone replacement therapy
by type, timing, duration, and route of hormone replacement therapy
administration.
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Part III
RESULTS

7. GOUT PROJECTS
To investigate these aims three studies were carried out:
Study 1
Epidemiology of Gout in the United Kingdom:
A Population-Based Cohort Study with a Nested Case-Control Study
Study 2
Use of Diuretics and Risk of Incident Gout:
A Population-Based Case-Control Study
Study 3
Poorly Controlled Type 2 Diabetes Mellitus is Associated with a Decreased
Risk of Incident Gout:
A Population-Based Case-Control Study
Study 4
Use of Hormone Replacement Therapy and Risk of Incident Gout:
A Population-Based Case-Control Study
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Study 1
Epidemiology of Gout in the United Kingdom:
a Population-Based Cohort Study with
a Nested Case-Control Study
Saskia G. Bruderer1,2
1 Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and
Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel,
Switzerland
2 Hospital Pharmacy, University Hospital Basel, Basel, Switzerland
Unpublished
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ABSTRACT
Background and Objective
Detailed data on the course of incidence rates (IRs), demographic charac-
teristics, and initial treatment of gout over the last decades are scarce. We
aimed at assessing the IRs of and identify risk factors for incident gout.
Methods
Using data from the UK-based Clinical Practice Research Datalink (CPRD),
we conducted a cohort study with an embedded nested case-control study be-
tween 1990 and 2010. One control from the population at risk was matched to
each case (patients with a recorded incident gout diagnosis during follow-up)
on age, sex, calendar time, general practice, and number of years of active
history in the CPRD prior to the index date. We adjusted for potential con-
founders by applying multivariate conditional logistic regression analyses.
Results
A total of 91,790 patients had a recorded incident diagnosis of gout. The
estimated IR per 10,000 person-years (PYs) yielded 18.0 (95% confidence inter-
val [CI] 17.9−18.1), was markedly higher in man than in women, and increased
over time. It was highest in Wales for both sexes (22.9, 95% CI 22.4−23.4), and
reached a maximum in January and June. In the nested case-control study,
74.1% of patients were male. Current smoking was associated with a decreased
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adjusted odds ratio (OR) of 0.76 (95% CI 0.71−0.92). Increasing alcohol con-
sumption, comorbidities such as hypertension, kidney failure, congestive heart
failure, and ischemic heart disease, and antihypertensive comedication (except
and calcium channel blockers), were associated with an increased adjusted OR.
Gout treatment remained unchanged over time except for colchicine whose use
increased.
Conclusions
Incident gout was recorded in 18.0 patients per 10,000 PYs. Risk factors for
incident gout included alcohol consumption, comorbidities (especially kidney
failure and congestive heart failure), and antihypertensive comedication.
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INTRODUCTION
Gout is a common inflammatory, painful arthritis with acute onset (1, 2).
Gout results from a deposition of monosodium urate crystals in peripheral
joints and soft tissues due to elevated uric acid levels above threshold for
saturation (1). With the possibility of urate lowering treatment gout is the
only chronic arthritis that can be cured(3). Increasing age and male sex (4,
5), obesity (6, 7), alcohol intake (7, 8), hyperuricaemia (1, 5), and some co-
morbidities such as hypertension, cardiovascular diseases, or renal failure are
associated with gout (4, 7, 9).
The prevalence of gout was reported to be 1.4% between 1999 and 2005 (4,
10, 11) and 2.5% in 2012 (12) in the United Kingdom (UK) population. A
study derived from the United States (US)-based Claims database reported a
rising prevalence between 1990 and 1999 (13), while a study derived from the
UK-based Clinical Practice Research Datalink (CPRD) reported a relatively
stable incidence within this time frame (4). A recent study reported an in-
creasing prevalence and incidence after 1997 (12). Reported incidence rates
(IRs) derived from the UK range from 11.2 to 26.8 per 10,000 person-years
(PYs) and are the highest reported within Europe (10-12, 14, 15). Despite
publication of European (16) and UK (17) guidelines in 2006 and 2007, the
management of gout appears to be suboptimal. Especially, only a minority of
patients receives urate lowering therapy (12).
Taken together, detailed data on IRs, demographic characteristics, and
initial treatment of gout over the course of time are scarce. We therefore
conducted a cohort study with a nested case-control study to assess the IRs
between 1990 and 2010, as well as demographics and characteristics, comor-
bidities, co-medication and current treatment patterns of gout.
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METHODS
Study design and data source
We conducted a cohort study with a nested case-control study using data
from the UK-based CPRD, a large, primary care database that was estab-
lished in 1987. The individuals enrolled in the database are representative
of the UK population with regard to age, sex, geographic distribution, and
annual turnover rate (4, 18). The CPRD holds anonymised information re-
garding demographics, and patient characteristics, as well as lifestyle variables,
such as body mass index (BMI), smoking status, and alcohol consumption, and
information on symptoms, medical diagnoses, referrals to consultants, and hos-
pitalizations. General practitioners generate drug prescriptions electronically.
The database has been described in detail elsewhere (19, 20) and has been
validated extensively (21-25).
The Independent Scientific Advisory Committee (ISAC) for Medicines and
Healthcare products Regulatory Agency (MHRA) database research approved
the study.
Study population
Cohort population
For the cohort study we included all patients in the CPRD from the start
of the database in 1987 until 2010. We excluded patients with less than three
years of active history in the database prior to the start of follow-up. We
further excluded patients with a history of cancer (except non-melanoma skin
cancer), human immunodeficiency virus infection, or with any code for gout
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prior to the start of follow-up. We followed all patients from the start of
follow-up until they developed incident gout, died, left the practice, or follow-
up ended in the medical record (either because the study period ended or the
practice stopped delivering data), whichever occurred first.
Nested case-control population
The date of the first-time recorded gout diagnosis was subsequently referred
to as the index date. Additionally, to minimize misclassification, we excluded
patients with a diagnosis of hemochromatosis, osteoarthritis, septic arthritis,
or rheumatoid arthritis within 180 days prior to until 90 days after the index
date. From the cohort population, we identified at random one control patient
without any evidence of gout for each case patient, matched them on age
(same year of birth), sex, calendar time (same index date), general practice,
and number of years of active history in the CPRD prior to the index date.
Similar case definitions of gout have been used and validated in previous studies
based on CPRD data (4, 26, 27).
Statistical analysis
Cohort analysis
We assessed crude IRs with 95% CIs of gout per 10,000 PYs for the over-
all population derived from the CPRD, stratified by sex, age (<25, 25−44,
45−64, 65−84, and ≥85 years), year of incident diagnosis (1990−2010), region
within the UK (Northwest, Northeast, Yorkshire & The Humber, East Mid-
lands, West Midlands, East of England, Southwest, South Central, London,
Southeast Coast, Northern Ireland, Scotland, and Wales), and seasonality (by
month). Rates were calculated as the number of incident gout cases divided
by the total number of PYs at risk. PYs at risk were calculated by adding up
person-time from the start of follow-up until the end of follow-up.
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Nested case-control analysis
We conducted conditional logistic regression analyses to calculate relative
risk estimates as odds ratios (ORs) with 95% CIs for gout in association with
potential risk factors. A two-sided p-value of <0.05 was considered as sta-
tistically significant. The analyses were controlled for potential confounders
such as sex, age, calendar time, general practice, and years of previous his-
tory on the database by matching. When we analysed the exposure odds, we
adjusted for patient characteristics, comorbidities or concomitant drug use in
the multivariate analysis a priori if these potential confounders were predic-
tor variables for gout known from the literature, and build a core model with
these variables. The predictor variables included smoking status (non, cur-
rent, ex, unknown), body mass index (BMI 12.0−18.5, 18.5−24.9, 25−29.9,
≥30kg/m2, unknown), alcohol consumption (never/ex, current [1−9, 10−19,
≥20 units per week], unknown). For demographics we included additionally
the comorbidities hypertension, congestive heart failure, and renal failure, and
for the drug exposures potassium sparing diuretics, thiazide diuretics, thiazide-
like diuretics, loop diuretics, angiotensin-converting-enzyme inhibitors, beta-
blockers, calcium channel blockers, and nitrates.
All analyses were done using the statistical software SAS, version 9.3 (SAS
Institute Inc., Cary, North Carolina).
44
RESULTS
Cohort study
The initial study population for the cohort study encompassed 5,157,052
patients from the CPRD, whereof 2,367,908 (45.9%) were male and 2,789,144
(54.1%) were female.
The overall IR per 10,000 PYs was 18.0 (95% CI 17.9−18.1), 29.0 (95% CI
28.8−29.2) in men and 8.6 (95% CI 8.5−8.8) in women. The IR increased in
both sexes over time, especially between 1999 and 2010. In males, the IR per
10,000 PYs in 1990 was 15.7 (95% CI 14.3−17.1) and in 2010 39.0 (95% CI
37.8−40.2). In females, the IR per 10,000 PYs in 1990 yielded 3.3 (95% CI
2.7−3.9), and in 2010 11.8 (95% CI 11.2−12.4). The IR increase for the period
1999−2010 overall was 61.2%, 56.6% in males and 66.2% in females. For more
information see Figure 1.
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Figure 1 Sex differences in gout across age categories (blue: male popu-
lation; red: female population; green: overall population; dotted lines: 95%
confidence intervals; PYs: Person-Years)
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Stratification by age strata yielded increasing IRs over time in all age strata
except in patients <25 years. Age strata 64-84 years presented the greatest
increase over time (Figure 2).
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Figure 2 Age-specific annual incidence rates of gout in men (A) and women
(B) between 1990 and 2010 (blue: 64−84 years; green: 45−64 years; red:
25−44 years; orange: <25 years; dotted lines: 95% confidence intervals; PYs:
Person-Years)
Stratification by month of onset of incident gout presented highest IRs per
10,000 PYs in January (22.0, 95% CI 21.6−22.5) and June (21.7, 95% CI
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21.2−22.1). This was true across all time strata and for both sexes. How-
ever, the most recent time strata (2005−2010) reached the highest IR in June,
namely 45.1 per 10,000 PYs (95% CI 43.4−46.7) for men and 13.9 per 10,000
PYs (95% CI 13.0−14.7) for women (Figure 3).
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Figure 3 Seasonal incidence rates in 5 year strata in men (A) and women
(B) between 1990−2010 (blue: 2005−2010; green: 2000−2004; red: 1995−1999;
orange: 1990−1994; dotted lines: 95% confidence intervals; PYs: Person-
Years)
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Stratification by region and sex yielded highest IRs in Wales with 22.9 (95%
CI 22.4−23.4) per 10,000 PYs overall, 37.2 (95% CI 36.3−38.2) per 10,000 PYs
in men and 10.9 (95% CI 10.4−11.3) per 10,000 PYs in women (Figure 4).
Figure 4 Regional incidence rates from 1990−2010 in the overall Gout
population
Figure 5 Sex-specific regional incidence rates between 1990 and 2010
48
Nested case-control study
Demographic and disease factors
From the cohort population 91,790 patients developed incident gout during
follow-up, whereof 67,987 (74.1%) were male and 23,803 (25.9%) were female;
this resulted in a male to female ratio of 2.9:1. Current smoking was associated
with a decreased OR of 0.76 (95% CI 0.71−0.92). Increasing number of alcohol
units per week in current alcohol consumers was associated with an increasing
OR. Increasing number of general practitioner visits within the last year prior
to the index date presented increasing OR.
Comorbidities such as hypertension, kidney failure, congestive heart failure and
ischemic heart disease were associated with an increased adjusted OR of 2.03
(95%CI 1.98−2.08), 2.76 (95% CI 2.63−2.91), 3.02 (95% CI 2.82−3.24), and
1.33 (95% CI 1.29−1.38), respectively. Dyslipidaemia and stroke/transient is-
chemic attack (TIA) only marginally increased the risk estimate. Diabetes mel-
litus was associated with a decreased adjusted OR of 0.70 (95% CI 0.67−0.73).
For further results see Table 1.
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Table 1 Demographics and characteristics of patients with incident gout
and matched controls
Variable 
No. of cases (%) 
(n=91,790) 
No. of 
controls (%) 
(n=91,790) 
OR crude (95% 
CI) 
OR adj.* (95% CI) 
Sex° 
  Male 67987 (74.1) 67987 (74.1) NA NA 
  Female 23803 (25.9) 23803 (25.9) NA NA 
Age-group [years]° 
        
  <25 479 (0.5) 481 (0.5) NA NA 
  25-44 14711 (16.0) 14712 (16.0) NA NA 
  45-64 34441 (37.5) 34446 (37.5) NA NA 
  65-84 36789 (40.1) 36832 (40.1) NA NA 
  ≥85 5370 (5.9) 5319 (5.8) NA NA 
BMI-group [kg/m2] 
        
  12.0-18.4 441 (0.5) 1007 (1.1) 0.70 (0.62 - 0.79) 0.81 (0.71 - 0.92) 
  18.5-24.9 15946 (17.4) 25240 (27.5) NA NA 
  25.0-29.9 31081 (33.9) 26517 (28.9) 1.91 (1.86 - 1.96) 1.73 (1.68 - 1.79) 
  30.0-60.0 23325 (25.4) 11682 (12.7) 3.35 (3.24 - 3.45) 2.72 (2.63 - 2.82) 
  Unknown 20997 (22.9) 27344 (29.8) 1.11 (1.08 - 1.15) 1.42 (1.37 - 1.48) 
Smoking status 
        
  Non-smoker 38584 (42.0) 37021 (40.3) NA NA 
  Current smoker 13067 (14.2) 16548 (18.0) 0.74 (0.72 - 0.76) 0.76 (0.74 - 0.79) 
  Ex-smoker 26659 (29.0) 20245 (22.1) 1.34 (1.31 - 1.38) 1.11 (1.08 - 1.14) 
  Unknown 13480 (14.7) 17976 (19.6) 0.64 (0.62 - 0.66) 0.94 (0.90 - 0.99) 
Alcohol consumption (Units/week)§ 
       
  Never / Ex 10667 (11.6) 11822 (12.9) NA NA 
  Current unknown 15884 (17.3) 16035 (17.5) 1.11 (1.07 - 1.15) 1.18 (1.13 - 1.23) 
  Current 1-9 18589 (20.3) 20640 (22.5) 1.05 (1.02 - 1.09) 1.16 (1.11 - 1.20) 
  Current 10-19 11259 (12.3) 9228 (10.1) 1.49 (1.43 - 1.55) 1.69 (1.61 - 1.76) 
  Current >20 16175 (17.6) 8356 (9.1) 2.42 (2.33 - 2.52) 2.86 (2.73 - 2.99) 
  Unknown 19216 (20.9) 25709 (28.0) 0.79 (0.76 - 0.82) 1.09 (1.03 - 1.14) 
GP visits last year 
        
  0-2 17527 (19.1) 29725 (32.4) NA NA 
  3-4 6266 (6.8) 7420 (8.1) 1.54 (1.48 - 1.60) 1.45 (1.38 - 1.51) 
  5-9 13534 (14.7) 13761 (15.0) 1.95 (1.89 - 2.01) 1.75 (1.69 - 1.82) 
  ≥10 54463 (59.3) 40884 (44.5) 3.21 (3.12 - 3.30) 2.38 (2.31 - 2.46) 
Comorbidities  
        
  Hypertension 39967 (43.5) 24090 (26.2) 2.58 (2.52 - 2.64) 2.03 (1.98 - 2.08) 
  Diabetes mellitus 7561 (8.2) 6530 (7.1) 1.18 (1.14 - 1.22) 0.70 (0.67 - 0.73) 
  Dyslipidaemia 13799 (15.0) 9073 (9.9) 1.72 (1.67 - 1.77) 1.20 (1.16 - 1.24) 
  Kidney failure 14311 (15.6) 7510 (8.2) 3.97 (3.79 - 4.16) 2.76 (2.63 - 2.91) 
  Congestive heart failure 8056 (8.8) 2517 (2.7) 3.90 (3.71 - 4.10) 3.07 (2.90 - 3.24) 
  Ischemic heart disease 16614 (18.1) 10408 (11.3) 1.86 (1.81 - 1.91) 1.33 (1.29 - 1.38) 
  Stroke/TIA 6464 (7.0) 4822 (5.3) 1.39 (1.34 - 1.45) 1.09 (1.04 - 1.14) 
BMI, body mass index; CI, confidence interval; OR, odds ratio; TIA, transient ischemic attack 
°Matching variables; NA: not applicable; § 1U (Unit) = 10ml of pure ethanol (8g of ethanol) 
*Adjusted for all variables in table: BMI, smoking status, alcohol consumption, hypertension, 
kidney failure, congestive heart failure, ischemic heart disease 
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Co-medication
Current use of most antihypertensive drugs except losartan and calcium
channel blockers yielded increased gout risks compared to never-use. More
details see Table 2.
Table 2 Current use of co-medication in patients with incident gout and
matched controls 
Co-medication 
No. of cases (%) 
(n=91,790) 
No. of 
controls (%) 
(n=91,790) 
OR crude (95% CI) 
OR adj.* (95% 
CI) 
ACE-I 19127 (20.8) 9810 (10.7) 2.71 (2.63 - 2.79) 1.46 (1.41 - 1.51) 
ARB (excl. Losartan) 4080 (4.4) 1992 (2.2) 2.30 (2.18 - 2.44) 1.18 (1.10 - 1.26) 
Losartan 1424 (1.6) 886 (1.0) 1.66 (1.52 - 1.81) 0.86 (0.78 - 0.94) 
Loop diuretics 13510 (14.7) 4109 (4.5) 4.70 (4.50 - 4.90) 3.28 (3.13 - 3.45) 
Thiazide diuretics 14545 (15.9) 7783 (8.5) 2.43 (2.35 - 2.51) 1.94 (1.87 - 2.01) 
Potassium-sparing 
diuretics 
2373 (2.6) 577 (0.6) 4.40 (4.01 - 4.83) 2.08 (1.87 - 2.30) 
Beta-blocker 19561 (21.3) 9973 (10.9) 2.57 (2.50 - 2.65) 1.82 (1.76 - 1.89) 
Calcium channel 
blockers 
13291 (14.5) 9384 (10.2) 1.73 (1.68 - 1.79) 0.98 (0.95 - 1.02) 
Nitrates 7647 (8.3) 4281 (4.7) 2.03 (1.95 - 2.12) 1.14 (1.09 - 1.20) 
Statins 17126 (18.7) 11437 (12.5) 1.90 (1.85 - 1.96) 1.04 (1.01 - 1.08) 
ASA low dose 15986 (17.4) 11410 (12.4) 1.72 (1.67 - 1.77) 1.01 (0.97 - 1.05) 
Pyrazinamide 22 (0.0) 15 (0.0) 1.47 (0.76 - 2.83) 1.39 (0.65 - 2.95) 
Cyclosporine 264 (0.3) 29 (0.0) 9.10 (6.20 - 13.36) 6.23 (4.12 - 9.41) 
ACE-I, Angiotensin-Converting-Enzyme-Inhibitors; ARB, Angiotensin-Receptor Blocker; ASA, 
Acetylsalicylic acid 
*Adjusted for all variables in table: BMI, smoking status, alcohol consumption, potassium 
sparing diuretics, thiazide diuretics, thiazide-like diuretics, loop diuretic, ACE-Is, beta-blockers, 
calcium channel blockers, nitrates 
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Trends in current gout treatment
Non-steroidal anti-inflammatory drugs (NSAIDs) were the most commonly
used drugs to treat acute gout. In the last decade the use of NSAIDs was
stable, while in the last two decades, the use of colchicine was increasing. The
use of allopurinol remained stable between 1999 and 2010 (Figure 5).
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Figure 5 Treatment patterns of patients with incident gout between 1990−2010
(red: NSAIDs; blue: colchicine; green: corticosteroids; orange: allopurinol)
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DISCUSSION
In this large population-based observational study from a UK primary care
setting, the overall IR of general practitioner-diagnosed gout was 18.0 (95% CI
17.9−18.1) per 10,000 PYs. IR estimates were higher in men than in women,
and gout tended to develop earlier in men. Since 1999, the IRs have slightly
increased, with the highest IR in men in 2010 (39.0 [95% CI 37.8−40.2] per
10,000 PYs); this was consistent with previous published IRs from the UK (4,
10, 12). Gout presented the highest IRs in January (22.0 [95% CI 21.6−22.5]
per 10,000 PYs) and June (21.7 [95% CI 21.2−22.1] per 10,000 PYs,). Fur-
thermore, the highest IR within the UK for both sexes was found in Wales.
From the cohort population 91,790 patients developed incident gout during
follow-up, which resulted in a male to female ratio of 2.9:1, consistent with
previous findings (4, 10, 12).
Alcohol consumption, comorbidities such as kidney failure, congestive heart
failure, ischemic heart disease, and hypertension, as well as antihypertensive
comedication (except losartan and calcium channel blockers), were associated
with an increased risk for incident gout, consistent with previous findings (9,
28). Current smoking status and a history of diabetes mellitus were associated
with a decreased risk of gout. Gout treatment patterns remained stable over
time, except colchicine whose use slightly increased over time.
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Cohort study
Gout prevalence within the UK has been reported to be 1.4% between 1999
and 2005 (4, 11), and has increased up to a prevalence of 2.5% in 2012 (12).
Only few studies assessed the incidence of gout within the UK with an IR of
14.0 per 10,000 PYs in 1981 (15), 11.9 to 18.0 per 10,000 PYs in the period
between 1990 and 1999 (4), 11.2 to 13.5 per 10,000 PYs between 1994 and 2007
(10), 26.8 per 10,000 PYs in the period between 2000 and 2007 (14), and 17.7
per 10,000 PYs in 2012 (12). The IR of this study with data derived between
1990 and 2010 was 18.0 per 10,000 PYs overall (29.0 per 10,000 PYs in men
and 8.6 per 10,000 PYs in women) and is comparable to previously published
data. In concordance with published findings we observed a rise in incidence
especially between 2000 and 2010 (12).
Gout presented the highest IRs in January (22.0 [95% CI 21.6−22.5] per
10,000 PYs) and June (21.7 [95% CI 21.2−22.1] per 10,000 PYs). Consistent
with our results, a previous study derived from England and Wales found the
highest IR in the summer period (14). Furthermore, only one study derived
from the CPRD reported regional differences for IRs (12). However, regional
variations for gout within the UK have been noted previously (29, 30). Small
aberrations of regional IRs may be explained by different lengths of follow-up in
the study from Kuo and co-workers (12). A possible explanation for the reason
in regional differences might be a difference in socioeconomic status, lifestyle,
and nutrition (30, 31). In concordance, increasing prevalence of overweight
and obesity (6), hypertension and cardiovascular diseases (6, 9), as well as
diabetes (32) might be further possible explanations for regional differences.
Nested case-control study
The onset of gout in men was mostly between 45−64 years of age, and in
women between 65-84 years of age, which is congruent with previous literature
(4). We observed a male to female ratio of 2.9:1 which is similar to previous
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published ratios (4, 10, 12). We detected a positive association for increasing
BMI, for increasing alcohol units per week, and for increasing general prac-
titioner visits within the last year prior to the index date and incident gout;
these findings were consistent with a previously published study from the UK-
based THIN database (10). We further observed a significantly decreased risk
estimate for current smokers when compared with non-smokers.
This study yielded modestly increasing prevalence for colchicine use, while
use of NSAIDs, corticosteroids, and allopurinol remained relatively unchanged,
consistent with previous findings (10). According to previous studies, gout
management is rather poor and treatment patterns differ between regions
(4, 12). Even after the new treatment guidelines of the British Society for
Rheumatology and British Health Professionals in Rheumatology (BSR/BHPR)
in 2007 (17) and European League Against Rheumatism Recommendations
(EULAR) in 2006 (16) treatment has not improved (12). There were some
novel approaches and key advances during the past decade that will hopefully
lead to improved management of hyperuricaemia and gout in the UK (3, 33).
Strengths and limitations
Our large population-based study has several strengths. We were in a po-
sition to study a large number of cases with incident gout in a well-established
primary care database (21-25). We were able to address the role of and ad-
just our analyses for important potential confounders such as BMI, smoking
status, alcohol consumption, renal failure, hypertension and concomitant drug
therapies. Since information on diseases and drug exposure was prospectively
entered in the CPRD in the absence of any study hypothesis, recall bias is not
an issue. Lastly, exclusion of all patients with less than three years of recorded
history in the database prior to the index date reduced the risk of including
prevalent rather than incident gout cases.
Some limitations of our study have to be acknowledged. Misclassification
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of some gout cases may occur, although a previous study has shown that gout
diagnoses are recorded with high validity in the CPRD (27). To minimize mis-
classification, we excluded patients with recorded diagnoses of other rheumatic
diagnoses around the index date, and we further excluded all patients with less
than 3 years of recorded history in the database prior to the index date to re-
duce the risk of including prevalent rather than incident gout cases.
We were not able to adjust for all known potential risk factors for gout
since, for example, dietary habits or physical activity (1, 6) are not routinely
recorded in the CPRD. However, we adjusted for BMI, a factor that is re-
lated both to physical activity and dietary habits. We were unable to assess
race/ethnicity because this information is also not consistently available in the
CPRD. However, as 86% of individuals living in the UK are white (34), our
results are most likely representative of that ethnic group. Finally, we could
not address potential confounding by socioeconomic status, but we partially
controlled for this parameter by matching cases and controls on general prac-
titioner, since patients from the same neighbourhood tend to see the same
general practitioner.
Conclusions
In summary, the incidence of gout in the UK has risen, especially between
1999 and 2010, and depends on season and region. The burden of gout re-
mains substantial in the UK and further research should be done based on
different patient populations such as patients with cardiovascular diseases or
renal failure.
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Objective. Use of diuretics has been associated
with an increased risk of gout. Data on different types of
diuretics are scarce. We undertook this study to inves-
tigate the association between use of loop diuretics,
thiazide or thiazide-like diuretics, and potassium-
sparing agents and the risk of developing incident gout.
Methods. We conducted a retrospective population-
based case–control analysis using the General Practice
Research Database established in the UK. We identified
case patients who were diagnosed as having incident gout
between 1990 and 2010. One control patient was matched
to each case patient for age, sex, general practice,
calendar time, and years of active history in the data-
base. We used conditional logistic regression to calcu-
late odds ratios (ORs) and 95% confidence intervals
(95% CIs), and we adjusted for potential confounders.
Results. We identified 91,530 incident cases of
gout and the same number of matched controls. Com-
pared to past use of diuretics from each respective drug
class, adjusted ORs for current use of loop diuretics,
thiazide diuretics, thiazide-like diuretics, and potassium-
sparing diuretics were 2.64 (95% CI 2.47–2.83), 1.70
(95% CI 1.62–1.79), 2.30 (95% CI 1.95–2.70), and 1.06
(95% CI 0.91–1.23), respectively. Combined use of loop
diuretics and thiazide diuretics was associated with the
highest relative risk estimates of gout (adjusted OR 4.65
[95% CI 3.51–6.16]). Current use of calcium channel
blockers or losartan slightly attenuated the risk of gout
in patients who took diuretics.
Conclusion. Use of loop diuretics, thiazide diuret-
ics, and thiazide-like diuretics was associated with an
increased risk of incident gout, although use of
potassium-sparing agents was not.
Gout is a painful, inflammatory, acute-onset ar-
thritis, characterized by deposition of monosodium urate
monohydrate crystals in affected joints (1,2). The dis-
ease is common in Western countries, with a reported
prevalence of1.4% in the overall UK population (3,4).
Gout predominantly affects men 40 years of age, and
prevalence increases as individuals age (3). Other risk
factors include obesity (5) and alcohol intake (6).
Most patients with gouty arthritis have hyperuri-
cemia, which is considered an important risk factor (2,7).
Hyperuricemia mainly results from decreased uric acid
excretion or increased uric acid reabsorption in the
kidneys. Diuretics, including loop diuretics, most thia-
zide diuretics, and potassium-sparing agents (such as
spironolactone or eplerenone), have been linked to
hyperuricemia via a presumed mechanism of decreased
renal uric acid excretion or increased uric acid reabsorp-
tion (8–10). Volume contraction and direct effects on
urate transporters in the proximal tubule have been
proposed as potential explanations (10). Studies have
demonstrated that hydrochlorothiazide increases urate
absorption by inhibition of organic anion transporter 4
(11), and the reduction of urate secretion by multidrug
resistance protein 4 (similar to furosemide) has also
been seen (9). Since diuretics predispose individuals to
Supported in part by a grant from the Senglet Foundation,
Switzerland.
1Saskia Bruderer, MSc: University of Basel and University
Hospital Basel, Basel, Switzerland; 2Michael Bodmer, MD: University
of Basel, Basel, Switzerland, and Bern University Hospital, Inselspital,
Bern, Switzerland; 3Susan S. Jick, DSc: Boston Collaborative Drug
Surveillance Program, Lexington, Massachusetts, and Boston Univer-
sity School of Public Health, Boston, Massachusetts; 4Christoph R.
Meier, PhD, MSc: University of Basel and University Hospital Basel,
Basel, Switzerland, and Boston Collaborative Drug Surveillance Pro-
gram, Lexington, Massachusetts, and Boston University School of
Public Health, Boston, Massachusetts.
Address correspondence to Christoph R. Meier, PhD, MSc,
Basel Pharmacoepidemiology Unit, University Hospital Basel, Spital-
strasse 26, CH-4031 Basel, Switzerland. E-mail: Christoph.Meier@
usb.ch.
Submitted for publication April 15, 2013; accepted in revised
form September 17, 2013.
185
63
hyperuricemia, use of these drugs has repeatedly been
associated with an increased risk of gouty arthritis
(5,10,12–21).
However, although most studies have demon-
strated an increased risk of gouty arthritis among those
who used diuretics, the magnitude of the observed risks
varied considerably among studies. Most investigators
studied diuretics as a class of drugs rather than as
individual drugs (5,13,14,16–19,21–23), and in many
studies, findings related to different types of diuretics
were based on small numbers of exposed patients (n 
50) (12,15,20). In addition, no association of the disease
with the duration of diuretic use has yet been reported.
Finally, potential confounding factors, such as concom-
itant treatment with antihypertensive drugs, acetylsali-
cylic acid (ASA), cyclosporine, or pyrazinamide, as well
as comorbid conditions, such as hypertension, chronic
kidney disease, congestive heart failure (CHF), and
diabetes mellitus (which all have been linked to an
increased risk of gout [3,24]), have not routinely been
controlled for in previous studies. We therefore con-
ducted an observational study to investigate the associ-
ation between use of different types of diuretics and the
risk of developing incident gouty arthritis.
Table 1. Demographic and clinical characteristics of the patients with gout and the age- and sex-matched control patients*
Variable
No. (%) of cases
(n  91,530)
No. (%) of controls
(n  91,530)
Crude OR
for incident gout
(95% CI) P
Adjusted OR
for incident gout
(95% CI) P
Sex
Male 67,823 (74.1) 67,823 (74.1) NA NA NA NA
Female 23,707 (25.9) 23,707 (25.9) NA NA NA NA
Age group, years
18–29 1,721 (1.9) 1,711 (1.9) NA NA NA NA
30–39 7,242 (7.9) 7,250 (7.9) NA NA NA NA
40–49 13,548 (14.8) 13,552 (14.8) NA NA NA NA
50–59 17,344 (19.0) 17,316 (18.9) NA NA NA NA
60–69 19,544 (21.4) 19,586 (21.4) NA NA NA NA
70–79 19,595 (21.4) 19,590 (21.4) NA NA NA NA
79 12,536 (13.7) 12,525 (13.7) NA NA NA NA
BMI group, kg/m2
12.0–18.4 440 (0.5) 1,003 (1.1) 0.67 (0.60–0.76) 0.001 0.76 (0.67–0.87) 0.001
18.5–24.9 15,912 (17.4) 25,050 (27.4) 1 (referent) NA 1 (referent) NA
25.0–29.9 31,027 (33.9) 26,518 (29.0) 1.89 (1.84–1.94) 0.001 1.72 (1.67–1.77) 0.001
30.0–60.0 23,304 (25.5) 11,645 (12.7) 3.32 (3.22-3.43) 0.001 2.73 (2.64–2.83) 0.001
Unknown 20,847 (22.8) 27,314 (29.8) 1.09 (1.06-1.13) 0.001 1.42 (1.37–1.48) 0.001
Smoking status
Nonsmoker 38,532 (42.1) 36,776 (40.2) 1 (referent) NA 1 (referent) NA
Current smoker 13,031 (14.2) 16,388 (17.9) 0.74 (0.72–0.77) 0.001 0.76 (0.74–0.79) 0.001
Former smoker 26,625 (29.1) 20,348 (22.2) 1.33 (1.30–1.36) 0.001 1.10 (1.07–1.13) 0.001
Unknown 13,342 (14.6) 18,018 (19.7) 0.62 (0.60–0.64) 0.001 0.91 (0.87–0.95) 0.001
Alcohol use, units/week†
Never used 10,648 (11.6) 11,902 (13.0) 1 (referent) NA 1 (referent) NA
Current use
Unknown 15,816 (17.3) 15,995 (17.5) 1.12 (1.08–1.16) 0.001 1.17 (1.12–1.22) 0.001
1–9 18,574 (20.3) 20,280 (22.2) 1.08 (1.04–1.12) 0.001 1.16 (1.11–1.20) 0.001
10–19 11,261 (12.3) 9,460 (10.3) 1.47 (1.41–1.53) 0.001 1.63 (1.56–1.71) 0.001
20 16,171 (17.7) 8,255 (9.0) 2.48 (2.38–2.58) 0.001 2.83 (2.70–2.96) 0.001
Unknown 19,060 (20.8) 25,638 (28.0) 0.79 (0.76–0.82) 0.001 1.08 (1.02–1.13) 0.004
Comorbidities
Hypertension 39,890 (43.6) 23,904 (26.1) 2.61 (2.55–2.67) 0.001 2.05 (2.00–2.10) 0.001
Diabetes mellitus 7,555 (8.3) 6,416 (7.0) 1.20 (1.16–1.25) 0.001 0.72 (0.69–0.75) 0.001
Dyslipidemia 13,798 (15.1) 9,064 (9.9) 1.72 (1.67–1.78) 0.001 1.20 (1.15–1.24) 0.001
Chronic kidney disease 14,328 (15.7) 7,490 (8.2) 4.03 (3.85–4.22) 0.001 2.83 (2.69–2.98) 0.001
CHF 8,038 (8.8) 2,503 (2.7) 3.93 (3.73–4.13) 0.001 3.18 (3.01–3.36) 0.001
Ischemic heart disease 16,584 (18.1) 10,487 (11.5) 1.84 (1.79–1.89) 0.001 1.30 (1.26–1.34) 0.001
Stroke/TIA 6,453 (7.1) 4,819 (5.3) 1.40 (1.34–1.45) 0.001 1.10 (1.05–1.15) 0.001
* Patients without evidence of gout served as controls. Controls were additionally matched for general practice, calendar time, and years of active
history in the database. The odds ratios (ORs) were adjusted for the following variables: body mass index (BMI), smoking status, alcohol
consumption, hypertension, chronic kidney disease, congestive heart failure (CHF), and ischemic heart disease. 95% CI  95% confidence interval;
NA  not applicable; TIA  transient ischemic attack.
† One unit is equivalent to 10 ml of pure ethanol (8 gm of ethanol).
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PATIENTS AND METHODS
Data source. Data were derived from the General
Practice Research Database, a large, UK-based primary care
database that was established in 1987. It encompasses data on
some 7 million patients registered with selected general prac-
titioners (7% of the UK population is represented in the
database) (25–27). The individuals enrolled in the database are
representative of the UK population with regard to age, sex,
geographic distribution, and annual turnover rate (3,28,29).
General practitioners have been trained to record medical
information for research purposes using standard software
and coding systems. The General Practice Research Database
holds anonymized information regarding demographics and
patient characteristics, as well as lifestyle variables, such as
body mass index (BMI), smoking status, and alcohol consump-
tion, and information on symptoms, medical diagnoses, refer-
rals to consultants, and hospitalizations. General practitioners
generate drug prescriptions electronically using a coded drug
dictionary; therefore, prescriptions include the name of the
preparation, route of administration, dose of a single unit, and
number of units prescribed. The database has been described
in detail elsewhere (30,31) and has been validated extensively
(26,32–35). Data from the General Practice Research Data-
base have been used in numerous epidemiologic studies
(27,30,31,36,37), including studies pertaining to gout (3,38,39).
The Independent Scientific Advisory Committee for Medi-
cines and Healthcare products Regulatory Agency database
research approved this study.
Study population. Case patients. Using READ codes (a
standard clinical terminology system), we identified all patients
who were 18 years of age and who had received a first-time
diagnosis of gout between 1990 and 2010. For this study, the
index date is the date at which the first diagnosis of gout was
received.
Exclusion criteria. We excluded all patients with 3
years of recorded history in the database prior to the index
date, as well as all patients with any recorded cancer diagnosis
(except nonmelanoma skin cancer) or a human immunodefi-
ciency virus infection prior to the index date. Additionally, we
excluded all patients who were diagnosed as having hemochro-
matosis, osteoarthritis, septic arthritis, or rheumatoid arthritis
within the 180 days that preceded the index date or within the
90 days that followed the index date. Similar case definitions of
gout have been used and validated in previous studies based on
General Practice Research Database data (3,38,39).
Control patients. From the base population, one control
patient without any evidence of gout was matched at random
to each gout case. Cases and controls were matched for
calendar time (same index date), age (same year of birth), sex,
general practice, and number of years of active history in the
General Practice Research Database prior to the index date.
We applied the same exclusion criteria to control patients as to
case patients.
Definition and classification of diuretic use. We as-
sessed the records of cases and controls to determine their use
of different types of diuretics prior to the index date. We
classified the diuretics into 4 groups according to World
Health Organization (WHO) classification: loop diuretics,
thiazide diuretics, thiazide-like diuretics, and potassium-
sparing diuretics.
Exposed patients were classified as follows, based on
the date the last prescription was issued: “current users”
(last prescription issued 1–180 days prior to the index date),
“past users” (last prescription issued 180 days prior to the
index date), or “non-users” (no prescription issued prior to the
index date). Most diuretics are available in packages of 90
tablets or more; therefore, we chose a cutoff date of 180 days
prior to the index date to increase the likelihood of properly
separating current users of diuretics from past users. Duration
of exposure was classified as follows, based on the number of
recorded prescriptions for the various types of diuretics prior
to the index date: short-term duration of use (1–9 prescrip-
tions), intermediate duration of use (10–19 prescriptions), or
long-term duration of use (20 prescriptions).
Covariates and sensitivity analyses. For both cases and
controls, we assessed whether arterial hypertension, chronic
kidney disease, ischemic heart disease, CHF, transient isch-
emic attack (TIA)/stroke, diabetes mellitus, or dyslipidemia
Table 2. Concomitant medications taken by the patients with gout and the matched control patients (current use)*
Concomitant medication
No. (%) of cases
(n  91,530)
No. (%) of controls
(n  91,530)
Crude OR
for incident gout
(95% CI) P
Adjusted OR
for incident gout
(95% CI) P
ACE inhibitor 19,121 (20.9) 9,759 (10.7) 1.04 (1.00–1.10) 0.073 1.14 (1.08–1.20) 0.001
ARB (excluding losartan) 4,086 (4.5) 1,979 (2.2) 1.07 (0.95–1.21) 0.289 1.24 (1.07–1.42) 0.003
Losartan 1,429 (1.6) 896 (1.0) 0.74 (0.64–0.85) 0.001 0.89 (0.76–1.04) 0.150
Beta-blockers 19,540 (21.4) 10,048 (11.0) 1.60 (1.54–1.67) 0.001 1.66 (1.59–1.73) 0.001
Calcium-channel blockers 13,290 (14.5) 9,425 (10.3) 0.76 (0.73–0.80) 0.001 0.87 (0.83–0.92) 0.001
Nitrates 7,641 (8.4) 4,381 (4.8) 1.29 (1.23–1.36) 0.001 1.14 (1.08–1.21) 0.001
Statins 17,142 (18.7) 11,502 (12.6) 1.09 (1.02–1.17) 0.010 0.95 (0.88–1.03) 0.228
Low-dose ASA 15,983 (17.5) 11,444 (12.5) 1.01 (0.97–1.06) 0.560 0.97 (0.92–1.03) 0.284
Pyrazinamide 22 (0.0) 20 (0.0) 0.88 (0.46–1.67) 0.693 0.94 (0.46–1.91) 0.855
Cyclosporine 263 (0.3) 39 (0.0) 1.56 (0.89–2.71) 0.120 1.56 (0.84–2.87) 0.157
* The odds ratios (ORs) were adjusted for the following variables: body mass index, smoking status, alcohol consumption, and use of
potassium-sparing diuretics, thiazide diuretics, thiazide-like diuretics, loop diuretics, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers,
calcium-channel blockers, and nitrates prior to the index date. 95% CI  95% confidence interval; ARB  angiotensin II receptor blocker; ASA 
acetylsalicylic acid.
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had ever been recorded prior to the index date. Furthermore,
we assessed the independent associations of antihypertensive
drugs (beta-blockers, angiotensin-converting enzyme [ACE]
inhibitors, angiotensin II receptor blockers [ARBs], or
calcium-channel blockers), organic nitrates, statins, pyrazin-
amide, cyclosporine, and low-dose ASA prior to the index
date. Additionally, we classified cases and controls accord-
ing to their smoking status (nonsmoker, current smoker,
past smoker, or unknown), BMI (25 kg/m2, 25–29.9 kg/m2,
30–59.9 kg/m2, or unknown), alcohol consumption (never,
current, past, or unknown), and alcohol use (1–9 units per
week, 10–19 units per week, 20 units per week), and we
assessed these covariates as potential confounders.
In a predefined sensitivity analysis, we restricted the
analysis to cases and controls who had received only one type
of diuretic or fixed combinations thereof. In addition, to
further address potential bias by indication, we stratified our
analyses by arterial hypertension, chronic kidney disease, and
CHF. These comorbidities are all linked to an increased risk
of gout and may be important confounders of the association
of interest. Finally, we assessed the risk of gout in association
with use of diuretics in the subset of cases (and their controls)
who were treated with nonsteroidal antiinflammatory drugs
(NSAIDs), colchicine, or uricosuric/uricostatic drugs within 7,
30, and 90 days of the index date, respectively.
Statistical analysis.Conditional logistic regression ana-
lysis was performed using SAS statistical software (version 9.3;
SAS Institute) to calculate relative risk estimates as odds ratios
(ORs) with 95% confidence intervals (95% CIs). P values less
than 0.05 (2-sided) were considered significant. In univariate
Table 3. ORs for incident gout in association with current use of different types of diuretics*
Diuretics
No. (%) of cases
(n  91,530)
No. (%) of controls
(n  91,530)
Crude OR
(95% CI) P
Adjusted OR
(95% CI) P
Loop diuretics
Never used 74,177 (81.0) 84,387 (92.2) 0.57 (0.54–0.60) 0.001 0.75 (0.71–0.80) 0.001
Current use (180 days)
Overall 13,487 (14.7) 4,136 (4.5) 2.63 (2.48–2.80) 0.001 2.64 (2.47–2.83) 0.001
1–9 prescriptions 2,652 (2.9) 1,104 (1.2) 1.81 (1.66–1.98) 0.001 1.95 (1.77–2.15) 0.001
10–19 prescriptions 2,330 (2.6) 780 (0.9) 2.36 (2.14–2.60) 0.001 2.36 (2.12–2.62) 0.001
20 prescriptions 8,505 (9.3) 2,252 (2.5) 3.18 (2.96–3.42) 0.001 3.16 (2.93–3.42) 0.001
Past use (180 days)
Overall 3,866 (4.2) 3,007 (3.3) 1 (referent) NA 1 (referent) NA
Thiazide diuretics
Never used 68,835 (75.2) 78,335 (85.6) 0.49 (0.47–0.51) 0.001 0.85 (0.81–0.88) 0.001
Current use (180 days)
Overall 13,332 (14.6) 7,203 (7.9) 1.16 (1.11–1.22) 0.001 1.70 (1.62–1.79) 0.001
1–9 prescriptions 2,605 (2.9) 1,483 (1.6) 1.05 (0.97–1.13) 0.209 1.51 (1.39–1.64) 0.001
10–19 prescriptions 2,463 (2.7) 1,297 (1.4) 1.15 (1.06–1.24) 0.001 1.64 (1.51–1.79) 0.001
20 prescriptions 8,264 (9.0) 4,423 (4.8) 1.21 (1.15–1.27) 0.001 1.81 (1.71–1.92) 0.001
Past use (180 days)
Overall 9,363 (10.2) 5,992 (6.6) 1 (referent) NA 1 (referent) NA
Thiazide-like diuretics
Never used 89,258 (97.5) 90,376 (98.7) 0.59 (0.53–0.65) 0.001 0.95 (0.85–1.07) 0.425
Current use (180 days)
Overall 1,260 (1.4) 537 (0.6) 1.45 (1.25–1.67) 0.001 2.30 (1.95–2.70) 0.001
1–9 prescriptions 314 (0.3) 130 (0.1) 1.47 (1.17–1.85) 0.001 2.08 (2.61–2.70) 0.001
10–19 prescriptions 270 (0.3) 101 (0.1) 1.64 (1.27–2.10) 0.001 2.36 (1.79–3.12) 0.001
20 prescriptions 676 (0.7) 306 (0.3) 1.37 (1.16–1.62) 0.001 2.44 (2.01–2.97) 0.001
Past use (180 days)
Overall 1,012 (1.1) 617 (0.7) 1 (referent) NA 1 (referent) NA
Potassium-sparing diuretics
Never used 87,452 (95.5) 90,392 (98.8) 0.31 (0.28–0.34) 0.001 0.62 (0.55–0.69) 0.001
Current use (180 days)
Overall 2,372 (2.6) 572 (0.6) 1.37 (1.20–1.57) 0.001 1.06 (0.91–1.23) 0.470
1–9 prescriptions 769 (0.8) 182 (0.2) 1.37 (1.14–1.66) 0.001 1.14 (0.92–1.40) 0.230
10–19 prescriptions 516 (0.6) 109 (0.1) 1.57 (1.25–1.98) 0.001 1.21 (0.94–1.57) 0.141
20 prescriptions 1,087 (1.2) 281 (0.3) 1.29 (1.10–1.52) 0.002 0.96 (0.80–1.15) 0.623
Past use (180 days)
Overall 1,706 (1.9) 566 (0.6) 1 (referent) NA 1 (referent) NA
* The odds ratios (ORs) were adjusted for the following variables: body mass index, smoking status, alcohol consumption, and use of
angiotensin-converting enzyme inhibitors, beta-blockers, calcium-channel blockers, and nitrates, as well as concomitant use of diuretic drugs of other
classes prior to the index date. Loop diuretics included mainly furosemide and bumetanide, as well as torsemide. Thiazide diuretics included mainly
bendroflumethiazide, as well as hydroflumethiazide, hydrochlorothiazide, chlorothiazide, polythiazide, cyclopenthiazide, and methyclothiazide.
Thiazide-like diuretics included mainly indapamide and chlorthalidone, as well as metolazone, quinethazone, xipamide, mefruside, clorexolone, and
clopamide. Potassium-sparing diuretics included mainly spironolactone and amiloride, as well as eplerenone and triamterene. 95% CI  95%
confidence interval; NA  not applicable.
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analysis, we explored the association of arterial hypertension,
chronic kidney disease, ischemic heart disease, CHF, TIA/
stroke, diabetes mellitus, dyslipidemia, smoking status, BMI,
alcohol consumption, as well as use of ACE inhibitors, beta-
blockers, calcium-channel blockers, nitrates, pyrazinamide,
cyclosporine, statins, and low-dose ASA, with the risk of gout.
We tested the association of each of these potential confound-
ers in multivariate analyses and included them in the final
model if they altered the association of diuretic use with the
risk of gout by 10%. To avoid overadjustment, we did not
include arterial hypertension, chronic kidney disease, and CHF
in the final model, since diuretics are routinely used to treat
these medical conditions. However, we stratified our analyses
by these important comorbidities.
RESULTS
The study population encompassed 91,530 pa-
tients with a first-time diagnosis of gout and 91,530
matched control patients. Of these, 25.9% were female,
and 74.1% were male. The mean  SD age at the index
date was 69  14.5 years in women and 59  15.3 years
in men. Time of active history in the database prior to
the index date was 11.4  5.3 years for cases and
controls. Being overweight or obese was associated with
an increased risk of gout, as was alcohol consumption
(where the risk increased as alcohol use increased),
while current smoking was associated with a decreased
risk of gout.
Comorbidities such as arterial hypertension, dys-
lipidemia, chronic kidney disease, CHF, ischemic heart
disease, and TIA/stroke were all associated with an
increased risk of incident gout (Table 1). Analysis of
treatment with most antihypertensive drugs, except lo-
sartan and calcium-channel blockers (which were both
associated with decreased relative risks of gout), re-
vealed increased gout risks. Cyclosporine therapy was
also associated with an increased risk of gout, while
neither low-dose ASA nor statin use was associated with
an altered risk (Table 2).
Compared with past use of diuretics from the
Table 4. ORs for incident gout in association with current use of combinations of diuretics of different drug classes*
Diuretics
No. (%) of cases
(n  91,530)
No. (%) of controls
(n  91,530)
Crude OR
(95% CI) P
Adjusted OR
(95% CI) P
None 51,433 (56.2) 70,034 (76.5) NA NA NA NA
Loop diuretics
Current use 4,303 (4.7) 1,644 (1.8) 3.29 (2.96–3.67) 0.001 3.01 (2.69–3.37) 0.001
Past use 1,070 (1.2) 1,216 (1.3) 1 (referent) NA 1 (referent) NA
Loop and thiazide diuretics
Current use 469 (0.5) 103 (0.1) 5.03 (3.84–6.60) 0.001 4.65 (3.51–6.16) 0.001
Past use 352 (0.4) 382 (0.4) 1 (referent) NA 1 (referent) NA
Loop and thiazide-like diuretics
Current use 34 (0.0) 9 (0.0) 4.59 (1.47–14.30) 0.009 3.66 (1.12–12.02) 0.032
Past use 12 (0.0) 14 (0.0) 1 (referent) NA 1 (referent) NA
Loop and potassium-sparing
diuretics
Current use 867 (1.0) 182 (0.2) 5.22 (3.49–7.80) 0.001 4.53 (2.96–6.93) 0.001
Past use 65 (0.1) 67 (0.1) 1 (referent) NA 1 (referent) NA
Thiazide diuretics
Current use 9,732 (10.6) 5,605 (6.1) 1.91 (1.79–2.04) 0.001 1.90 (1.77–2.04) 0.001
Past use 2,851 (3.1) 3,029 (3.3) 1 (referent) NA 1 (referent) NA
Thiazide and potassium-sparing
diuretics
Current use 39 (0.0) 24 (0.0) 1.14 (0.46–2.78) 0.782 1.22 (0.48–3.06) 0.679
Past use 22 (0.0) 14 (0.0) 1 (referent) NA 1 (referent) NA
Thiazide-like diuretics
Current use 567 (0.6) 282 (0.3) 2.09 (1.55–2.82) 0.001 2.08 (1.53–2.85) 0.001
Past use 139 (0.2) 131 (0.1) 1 (referent) NA 1 (referent) NA
Potassium-sparing diuretics
Current use 61 (0.1) 48 (0.1) 1.39 (0.79–2.42) 0.252 1.13 (0.63–2.03) 0.674
Past use 57 (0.1) 61 (0.1) 1 (referent) NA 1 (referent) NA
Other combinations 19,457 (21.3) 8,685 (9.5) NA NA NA NA
* The odds ratios (ORs) were adjusted for the following variables: body mass index, smoking status, alcohol consumption, and use of
angiotensin-converting enzyme inhibitors, beta-blockers, calcium-channel blockers, and nitrates prior to the index date. Loop diuretics included
mainly furosemide and bumetanide, as well as torsemide. Thiazide diuretics included mainly bendroflumethiazide, as well as hydroflumethiazide,
hydrochlorothiazide, chlorothiazide, polythiazide, cyclopenthiazide, and methyclothiazide. Thiazide-like diuretics included mainly indapamide and
chlorthalidone, as well as metolazone, quinethazone, xipamide, mefruside, clorexolone, and clopamide. Potassium-sparing diuretics included mainly
spironolactone and amiloride, as well as eplerenone and triamterene. 95% CI  95% confidence interval; NA  not applicable.
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Table 5. Risk of gout in association with the use of different types of diuretics, stratified by the presence or absence of chronic kidney disease*
No. (%)
of cases
No. (%)
of controls
Crude OR
(95% CI) P
Adjusted OR
(95% CI) P
Chronic kidney disease
Loop diuretics
Never used 6,707 (46.8) 5,064 (67.6) 0.84 (0.76–0.93) 0.001 1.01 (0.91–1.13) 0.821
Current use (180 days)
Overall 6,313 (44.1) 1,506 (20.1) 3.01 (2.69–3.37) 0.001 3.02 (2.67–3.40) 0.001
1–9 prescriptions 870 (6.1) 277 (3.7) 2.08 (1.75–2.47) 0.001 2.26 (1.88–2.72) 0.001
10–19 prescriptions 955 (6.7) 236 (3.2) 2.83 (2.36–3.38) 0.001 2.92 (2.41–3.53) 0.001
20 prescriptions 4,488 (31.3) 993 (13.3) 3.35 (2.97–3.78) 0.001 3.30 (2.90–3.76) 0.001
Past use (180 days)
Overall 1,308 (9.1) 920 (12.3) 1 (referent) NA 1 (referent) NA
Thiazide diuretics
Never used 7,105 (49.6) 4,003 (53.4) 0.51 (0.48–0.54) 0.001 1.01 (0.93–1.09) 0.886
Current use (180 days)
Overall 3,616 (25.2) 1,746 (23.3) 1.16 (1.08–1.25) 0.001 1.46 (1.33–1.61) 0.001
1–9 prescriptions 418 (2.9) 196 (2.6) 0.89 (0.74–1.08) 0.236 1.50 (1.21–1.86) 0.001
10–19 prescriptions 487 (3.4) 240 (3.2) 0.89 (0.75–1.06) 0.208 1.34 (1.10–1.62) 0.003
20 prescriptions 2,711 (18.9) 1,310 (17.5) 0.99 (0.90–1.08) 0.766 1.48 (1.34–1.65) 0.001
Past use (180 days)
Overall 3,607 (25.2) 1,741 (23.2) 1 (referent) NA 1 (referent) NA
Thiazide-like diuretics
Never used 13,493 (94.2) 7,126 (95.1) 0.83 (0.70–0.99) 0.042 1.15 (0.94–1.40) 0.168
Current use (180 days)
Overall 405 (2.8) 154 (2.1) 1.29 (0.99–1.67) 0.059 1.95 (1.45–2.61) 0.001
1–9 prescriptions 94 (0.7) 38 (0.5) 1.25 (0.81–1.92) 0.317 1.52 (0.93–2.48) 0.092
10–19 prescriptions 72 (0.5) 31 (0.4) 1.00 (0.62–1.60) 0.983 1.38 (0.82–2.33) 0.223
20 prescriptions 239 (1.7) 85 (1.1) 1.42 (1.04–1.94) 0.029 2.40 (1.69–3.41) 0.001
Past use (180 days)
Overall 430 (3.0) 210 (2.8) 1 (referent) NA 1 (referent) NA
Potassium-sparing diuretics
Never used 12,240 (85.4) 7,087 (94.6) 0.36 (0.31–0.43) 0.001 0.59 (0.49–0.71) 0.001
Current use (180 days)
Overall 1,228 (8.6) 212 (2.8) 1.25 (1.00–1.56) 0.056 1.32 (1.04–1.68) 0.022
1–9 prescriptions 375 (2.6) 56 (0.7) 1.40 (1.00–1.95) 0.049 1.38 (0.97–1.97) 0.073
10–19 prescriptions 258 (1.8) 35 (0.5) 1.53 (1.02–2.29) 0.038 1.76 (1.15–2.69) 0.010
20 prescriptions 595 (4.2) 121 (1.6) 1.09 (0.84–1.41) 0.532 1.17 (0.88–1.55) 0.280
Past use (180 days)
Overall 860 (6.0) 191 (2.6) 1 (referent) NA 1 (referent) NA
No chronic kidney disease
Loop diuretics
Never used 67,470 (87.4) 79,323 (94.4) 0.55 (0.52–0.59) 0.001 0.74 (0.69–0.79) 0.001
Current use (180 days)
Overall 7,174 (9.3) 2,630 (3.1) 2.20 (2.03–2.38) 0.001 2.15 (1.98–2.34) 0.001
1–9 prescriptions 1,782 (2.3) 827 (1.0) 1.67 (1.50–1.85) 0.001 1.77 (1.58–1.98) 0.001
10–19 prescriptions 1,375 (1.8) 544 (0.6) 1.97 (1.75–2.22) 0.001 1.84 (1.61–2.09) 0.001
20 prescriptions 4,017 (5.2) 1,259 (1.5) 2.68 (2.44–2.93) 0.001 2.57 (2.33–2.84) 0.001
Past use (180 days)
Overall 2,558 (3.3) 2,087 (2.5) 1 (referent) NA 1 (referent) NA
Thiazide diuretics
Never used 61,730 (80.0) 74,332 (88.4) 0.50 (0.48–0.53) 0.001 0.82 (0.78–0.86) 0.001
Current use (180 days)
Overall 9,716 (12.6) 5,457 (6.5) 1.28 (1.22–1.36) 0.001 1.61 (1.52–1.71) 0.001
1–9 prescriptions 2,187 (2.8) 1,287 (1.5) 1.12 (1.03–1.22) 0.006 1.42 (1.30–1.55) 0.001
10–19 prescriptions 1,976 (2.6) 1,057 (1.3) 1.25 (1.15–1.37) 0.001 1.57 (1.43–1.73) 0.001
20 prescriptions 5,553 (7.2) 3,113 (3.7) 1.37 (1.29–1.46) 0.001 1.72 (1.60–1.84) 0.001
Past use (180 days)
Overall 5,756 (7.5) 4,251 (5.1) 1 (referent) NA 1 (referent) NA
Thiazide-like diuretics
Never used 75,765 (98.1) 83,250 (99.1) 0.57 (0.50–0.65) 0.001 0.93 (0.80–1.07) 0.318
Current use (180 days)
Overall 855 (1.1) 383 (0.5) 1.55 (1.29–1.86) 0.001 2.09 (1.72–2.56) 0.001
1–9 prescriptions 220 (0.3) 92 (0.1) 1.61 (1.22–2.14) 0.001 2.01 (1.47–2.74) 0.001
10–19 prescriptions 198 (0.3) 70 (0.1) 1.90 (1.40–2.59) 0.001 2.25 (1.61–3.12) 0.001
20 prescriptions 437 (0.6) 221 (0.3) 1.41 (1.14–1.74) 0.002 2.07 (1.64–2.62) 0.001
Past use (180 days)
Overall 582 (0.8) 407 (0.5) 1 (referent) NA 1 (referent) NA
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respective diuretic drug classes, current use of loop
diuretics (adjusted OR 2.64 [95% CI 2.47–2.83]), thia-
zide diuretics (adjusted OR 1.70 [95% CI 1.62–1.79]),
and thiazide-like diuretics (adjusted OR 2.30 [95% CI
1.95–2.70]) was associated with increased risks of inci-
dent gout, although current use of potassium-sparing
diuretics (adjusted OR 1.06 [95% 0.91–1.23]) was not.
The risk increased in current users of loop diuretics as
the duration of use increased (Table 3).
Concomitant treatment with losartan attenuated
the ORs for gout in users of loop diuretics (adjusted OR
0.81 [95% CI 0.59–1.12]), thiazide diuretics (adjusted
OR 0.76 [95% CI 0.56–1.02]), and thiazide-like diuretics
(adjusted OR 0.85 [95% CI 0.39–1.86]), compared to
past use of losartan and current use of the respective
diuretic drugs. Similarly, concomitant treatment with
calcium-channel blockers decreased relative risk esti-
mates for gout in current users of loop diuretics (ad-
justed OR 0.64 [95% CI 0.57–0.72]) and thiazide diuret-
ics (adjusted OR 0.82 [95% CI 0.74–0.91]) compared to
past use of calcium-channel blockers and current use of
the respective diuretic drugs, although the same was not
true for thiazide-like diuretics (adjusted OR 1.31 [95%
CI 0.95–1.80]).
In the sensitivity analysis of the mutually exclu-
sive groups of different diuretic drug classes, current use
of loop diuretics (adjusted OR 3.01 [95% CI 2.69–3.37]),
combined use of loop diuretics and thiazide diuretics
(adjusted OR 4.65 [95% CI 3.51–6.16]), and combined
use of loop diuretics and potassium-sparing agents (ad-
justed OR 4.53 [95% CI 2.96–6.93]) yielded substantially
increased relative risk estimates (Table 4). When the
analysis was restricted to gout patients treated with
NSAIDs, colchicine, uricosuric drugs, or uricostatic
drugs, results did not materially differ from those of the
main analysis (data not shown). Stratification by pres-
ence or absence of arterial hypertension did not alter
results when compared to the results of the main analysis
(data not shown). Stratification by presence or absence
of chronic kidney disease also did not meaningfully alter
the relative risk estimates (Table 5). Finally, when we
stratified by presence or absence of CHF, relative risk
estimates remained increased in users of loop diuretics
and thiazide-like diuretics; however, among patients
who used thiazide diuretics, the significant increase in
gout risk overall was not observed in the subgroup with
CHF (Table 6).
To investigate whether using different cutoff
dates to define current diuretic drug use could impact
our findings, we tested different cutoff dates (90 days
and 180 days prior to the index date). No meaningful
difference was observed, but since packages could last
for 90 days, we used 180 days as the cutoff in all
analyses to increase the likelihood of properly separating
current from past use (data not shown).
DISCUSSION
Using the General Practice Research Database,
we explored the risk of incident gout in association with
the use of different diuretic drugs. Current use of loop
diuretics was associated with a markedly increased risk
of incident gout compared to past use. Use of thiazide
and thiazide-like diuretics was also associated with a
Table 5. (Cont’d)
No. (%) of
cases
No. (%) of
controls
Crude OR
(95% CI) P
Adjusted OR
(95% CI) P
Potassium-sparing diuretics
Never used 75,212 (97.4) 83,305 (99.1) 0.37 (0.33–0.42) 0.001 0.69 (0.60–0.79) 0.001
Current use (180 days)
Overall 1,144 (1.5) 360 (0.4) 1.39 (1.17–1.66) 0.001 1.26 (1.05–1.52) 0.015
1–9 prescriptions 394 (0.5) 126 (0.1) 1.38 (1.08–1.75) 0.010 1.29 (1.00–1.68) 0.053
10–19 prescriptions 258 (0.3) 74 (0.1) 1.52 (1.13–2.03) 0.005 1.25 (0.91–1.72) 0.162
20 prescriptions 492 (0.6) 160 (0.2) 1.35 (1.08–1.68) 0.008 1.24 (0.98–1.58) 0.074
Past use (180 days)
Overall 846 (1.1) 375 (0.4) 1 (referent) NA 1 (referent) NA
* For chronic kidney disease, 14,328 cases and 7,490 controls are represented. For no chronic kidney disease, 77,202 cases and 84,040 controls are
represented. The odds ratios (ORs) were adjusted for the following variables: body mass index, smoking status, alcohol consumption, and use of
angiotensin-converting enzyme inhibitors, beta-blockers, calcium-channel blockers, and nitrates, as well as the concomitant use of diuretic drugs of
other classes prior to the index date. Loop diuretics included mainly furosemide and bumetanide, as well as torsemide. Thiazide diuretics included
mainly bendroflumethiazide, as well as hydroflumethiazide, hydrochlorothiazide, chlorothiazide, polythiazide, cyclopenthiazide, and methylclothi-
azide. Thiazide-like diuretics included mainly indapamide and chlorthalidone, as well as metolazone, quinethazone, xipamide, mefruside,
clorexolone, and clopamide. Potassium-sparing diuretics included mainly spironolactone and amiloride, as well as eplerenone and triamterene. 95%
CI  95% confidence interval; NA  not applicable.
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Table 6. Risk of gout in association with the use of different types of diuretics, stratified by the presence or absence of congestive heart failure*
No. (%)
of cases
No. (%)
of controls
Crude OR
(95% CI) P
Adjusted OR
(95% CI) P
Congestive heart failure
Loop diuretics
Never used 1,237 (15.4) 714 (28.5) 0.96 (0.82–1.12) 0.581 1.20 (1.01–1.42) 0.036
Current use (180 days)
Overall 6,069 (75.5) 1,358 (54.3) 2.62 (2.28–3.01) 0.001 2.53 (2.18–2.94) 0.001
1–9 prescriptions 815 (10.1) 275 (11.0) 1.60 (1.33–1.94) 0.001 1.77 (1.45–2.17) 0.001
10–19 prescriptions 1,027 (12.8) 254 (10.1) 2.34 (1.94–2.84) 0.001 2.26 (1.84–2.76) 0.001
20 prescriptions 4,227 (52.6) 829 (33.1) 3.06 (2.643.55) 0.001 2.90 (2.48–3.40) 0.001
Past use (180 days)
Overall 732 (9.1) 431 (17.2) 1 (referent) NA 1 (referent) NA
Thiazide diuretics
Never used 5,735 (71.3) 1,817 (72.6) 0.79 (0.70–0.89) 0.001 1.01 (0.89–1.15) 0.898
Current use (180 days)
Overall 515 (6.4) 194 (7.8) 0.69 (0.57–0.85) 0.001 0.86 (0.69–1.07) 0.169
1–9 prescriptions 161 (2.0) 60 (2.4) 0.68 (0.49–0.94) 0.019 0.94 (0.66–1.35) 0.750
10–19 prescriptions 98 (1.2) 33 (1.3) 0.71 (0.47–1.09) 0.121 0.72 (0.46–1.13) 0.149
20 prescriptions 256 (3.2) 101 (4.0) 0.70 (0.54–0.90) 0.007 0.86 (0.65–1.14) 0.308
Past use (180 days)
Overall 1,788 (22.2) 492 (19.7) 1 (referent) NA 1 (referent) NA
Thiazide-like diuretics
Never used 7,823 (97.3) 2,451 (97.9) 0.84 (0.60–1.19) 0.322 1.20 (0.83–1.74) 0.333
Current use (180 days)
Overall 50 (0.6) 8 (0.3) 1.64 (0.71–3.77) 0.244 2.51 (1.04–6.06) 0.042
1–9 prescriptions 12 (0.1) 3 (0.1) 0.96 (0.25–3.62) 0.947 1.14 (0.28–4.69) 0.858
10–19 prescriptions 8 (0.1) 1 (0.0) 2.63 (0.31–22.72) 0.379 3.71 (0.42–32.82) 0.238
20 prescriptions 30 (0.4) 4 (0.2) 1.93 (0.64–5.86) 0.245 3.33 (1.02–10.87) 0.047
Past use (180 days)
Overall 165 (2.1) 44 (1.8) 1 (referent) NA 1 (referent) NA
Potassium-sparing diuretics
Never used 5,725 (71.2) 2,102 (84.0) 0.53 (0.45–0.63) 0.001 0.67 (0.56–0.81) 0.001
Current use (180 days)
Overall 1,416 (17.6) 228 (9.1) 1.18 (0.94–1.47) 0.149 1.22 (0.96–1.53) 0.101
1–9 prescriptions 434 (5.4) 70 (2.8) 1.17 (0.86–1.58) 0.326 1.22 (0.88–1.69) 0.225
10–19 prescriptions 341 (4.2) 41 (1.6) 1.64 (1.13–2.37) 0.010 1.70 (1.15–2.51) 0.008
20 prescriptions 641 (8.0) 117 (4.7) 1.03 (0.79–1.33) 0.852 1.05 (0.79–1.38) 0.755
Past use (180 days)
Overall 897 (11.2) 173 (6.9) 1 (referent) NA 1 (referent) NA
No congestive heart failure
Loop diuretics
Never used 72,940 (87.4) 83,673 (94.0) 0.60 (0.56–0.63) 0.001 0.81 (0.76–0.86) 0.001
Current use (180 days)
Overall 7,418 (8.9) 2,778 (3.1) 2.30 (2.14–2.47) 0.001 2.27 (2.10–2.45) 0.001
1–9 prescriptions 1,837 (2.2) 829 (0.9) 1.80 (1.63–1.99) 0.001 1.90 (1.70–2.12) 0.001
10–19 prescriptions 1,303 (1.6) 526 (0.6) 2.07 (1.83–2.33) 0.001 1.97 (1.73–2.24) 0.001
20 prescriptions 4,278 (5.1) 1,423 (1.6) 2.71 (4.49–2.94) 0.001 2.64 (2.41–2.89) 0.001
Past use (180 days)
Overall 3,134 (3.8) 2,576 (2.9) 1 (referent) NA 1 (referent) NA
Thiazide diuretics
Never used 63,100 (75.6) 76,518 (85.9) 0.49 (0.47–0.51) 0.001 0.81 (0.78–0.85) 0.001
Current use (180 days)
Overall 12,817 (15.4) 7,009 (7.9) 1.30 (1.24–1.36) 0.001 1.63 (1.55–1.72) 0.001
1–9 prescriptions 2,444 (2.9) 1,423 (1.6) 1.15 (1.07–1.24) 0.001 1.45 (1.34–1.58) 0.001
10–19 prescriptions 2,365 (2.8) 1,264 (1.4) 1.26 (1.17–1.37) 0.001 1.58 (1.45–1.72) 0.001
20 prescriptions 8,008 (9.6) 4,322 (4.9) 1.36 (1.29–1.44) 0.001 1.71 (1.61–1.81) 0.001
Past use (180 days)
Overall 7,575 (9.1) 5,500 (6.2) 1 (referent) NA 1 (referent) NA
Thiazide-like diuretics
Never used 81,435 (97.5) 87,925 (98.8) 0.58 (0.52–0.65) 0.001 0.95 (0.84–1.08) 0.428
Current use (180 days)
Overall 1,210 (1.4) 529 (0.6) 1.53 (1.32–1.78) 0.001 2.06 (1.74–2.43) 0.001
1–9 prescriptions 302 (0.4) 127 (0.1) 1.56 (1.23–1.98) 0.001 1.88 (1.44–2.45) 0.001
10–19 prescriptions 262 (0.3) 100 (0.1) 1.71 (1.32–2.21) 0.001 2.01 (1.52–2.65) 0.001
20 prescriptions 646 (0.8) 302 (0.3) 1.46 (1.22–1.74) 0.001 2.16 (1.77–2.63) 0.001
Past use (180 days)
Overall 847 (1.0) 573 (0.6) 1 (referent) NA 1 (referent) NA
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significantly increased risk of developing incident gout,
although use of potassium-sparing diuretics was not.
These findings were further strengthened by the results
obtained from the mutually exclusive model and from
the analysis that was restricted to cases with recorded
pharmacologic treatment of gout (results of which were
similar to those found in the main model). Of interest,
combined use of diuretics of different drug classes,
namely, loop diuretics in combination with thiazide
diuretics or potassium-sparing agents, further increased
the relative risk estimates. Of note, the risk increase in
association with different types of diuretics was most
pronounced in individuals who used loop diuretics and
was further increased by concomitant use of other
diuretic drugs. This observation is consistent with the
proposed mechanism of hypovolemia-induced increases
in renal reabsorption of urate (8–10).
Our results did not materially differ when the
analyses were stratified by the presence or absence of
important indications for diuretic drug use, such as
arterial hypertension or chronic kidney disease. How-
ever, in the analysis stratified by presence or absence of
CHF, use of thiazide diuretics was no longer associated
with an increased risk in patients with CHF. Taken
together, these findings indicate that residual confound-
ing by indication by arterial hypertension or chronic
kidney disease does not seem to explain our findings.
However, a recorded diagnosis of CHF must be consid-
ered as a confounder of the association between the risk
of gout and the use of thiazides (but not other types of
diuretics).
We observed a decreased relative risk estimate
for gout in current users of losartan or calcium-channel
blockers in combination with loop diuretics or thiazide
diuretics. This observation may be of clinical importance
for patients receiving diuretic therapy; treatment with
losartan and/or calcium-channel blockers may be con-
sidered in patients with an increased risk of gout where
appropriate.
To our knowledge, this large population-based
study of 90,000 patients with incident gout is the first
to assess the association of current versus past use of
diuretics of different groups on the risk of gout. In a
recent systematic review, Hueskes et al (10) reported on
the results of 2 randomized controlled trials (12,13) and
12 population-based studies that explored the associa-
tion between diuretics and gout. Randomized controlled
trials that were based on small numbers of participants
were limited to use of bendrofluazide (n  30) (12) and
the combination of hydrochlorothiazide/triamterene (n 
7) (13); a markedly increased risk of incident gout in
patients treated with these drugs was seen. Of the 12
available population-based studies, only the study by
Gurwitz et al (15) demonstrated the relative risks of
developing gout among individuals who used diuretic
drugs of a specific class (thiazide diuretics), while no
other studies differentiated between the various types of
diuretics. All but one study demonstrated an increased
risk of gout in association with diuretic drug use, al-
though relative risk estimates varied considerably (10).
In the study by Janssens et al (22), which included 70
cases of incident gout, the reported incidence rate ratio
of gout in association with use of diuretics was 0.6 (95%
CI 0.2–2.0) after adjustment for cardiovascular comor-
Table 6. (Cont’d)
No. (%)
of cases
No. (%)
of controls
Crude OR
(95% CI) P
Adjusted OR
(95% CI) P
Potassium sparing diuretics
Never used 81,727 (97.9) 88,290 (99.2) 0.42 (0.37–0.48) 0.001 0.72 (0.63–0.83) 0.001
Current use (180 days)
Overall 956 (1.1) 344 (0.4) 1.36 (1.14–1.62) 0.001 1.27 (1.05–1.55) 0.014
1–9 prescriptions 335 (0.4) 112 (0.1) 1.40 (1.09–1.80) 0.008 1.26 (0.96–1.66) 0.095
10–19 prescriptions 175 (0.2) 68 (0.1) 1.23 (0.90–1.68) 0.185 1.11 (0.79–1.56) 0.552
20 prescriptions 446 (0.5) 164 (0.2) 1.38 (1.11–1.73) 0.005 1.36 (1.07–1.74) 0.013
Past use (180 days)
Overall 809 (1.0) 393 (0.4) 1 (referent) NA 1 (referent) NA
* For congestive heart failure, 8,038 cases and 2,503 controls are represented. For no congestive heart failure, 83,492 cases and 89,027 controls are
represented. The odds ratios (ORs) were adjusted for the following variables: body mass index, smoking status, alcohol consumption, and use of
angiotensin-converting enzyme inhibitors, beta-blockers, calcium-channel blockers, and nitrates, as well as the concomitant use of diuretic drugs of
other classes prior to the index date. Loop diuretics included mainly furosemide and bumetanide, as well as torsemide. Thiazide diuretics included
mainly bendroflumethiazide, as well as hydroflumethiazide, hydrochlorothiazide, chlorothiazide, polythiazide, cyclopenthiazide, and methylclothi-
azide. Thiazide-like diuretics included mainly indapamide and chlorthalidone, as well as metolazone, quinethazone, xipamide, mefruside,
clorexolone, and clopamide. Potassium-sparing diuretics included mainly spironolactone and amiloride, as well as eplerenone and triamterene. 95%
CI  95% confidence interval; NA  not applicable.
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bidities such as hypertension, CHF, and myocardial
infarction. However, the number of participants in that
study was small, the reported 95% CIs were wide, and
results for specific diuretic drug classes were not re-
ported.
Potential confounding is an important issue when
exploring the risk of gout in association with use of
diuretics, since these drugs are used to treat medical
conditions (such as arterial hypertension, chronic kidney
disease, and CHF) that have themselves been linked to
an increased risk of gout (3,40). In addition, concomitant
treatment with medications from other drug classes,
such as antihypertensive drugs, has also been linked to
an altered risk of developing gout, as seen in this study
as well as in another (40). In our study, adjusting the
analyses for potential confounders markedly attenuated
relative risk estimates, but relative risk estimates re-
mained significantly increased among current users of
different types of diuretics. Furthermore, relative risk
estimates were slightly increased among current users of
loop diuretics as the number of prescriptions increased,
and relative risk estimates remained increased in analy-
ses stratified by presence or absence of arterial hyper-
tension, CHF, or chronic kidney disease, with the excep-
tion of use of thiazide diuretics in cases and controls with
recorded CHF. Taken together, these findings likely
suggest that loop, thiazide, and thiazide-like diuretics
play a role in the development of incident gout. How-
ever, the causality of such a relationship cannot be
proven in an observational study.
In our study and in accordance with the findings
of other studies, being overweight or obese (5,24),
consuming alcohol (6,24), and having comorbidities,
such as hypertension, chronic kidney disease, and CHF
(3,40), were associated with an increased risk of incident
gout. Use of ACE inhibitors and beta-blockers was
associated with marginally increased risks of incident
gout, while use of losartan and calcium-channel blockers
was associated with slightly decreased risks. These find-
ings were similar to the results reported by Choi et al in
a recently published General Practice Research
Database–based study (40).
Our large population-based study has several
strengths. We studied a large number of cases with
incident gout in a well-established validated primary
care database (26,32–35). Furthermore, we studied dif-
ferent types of diuretics and the role of the duration of
diuretic use, and we conducted various sensitivity ana-
lyses that yielded consistent findings. We further ad-
dressed the role of important potential confounders
such as BMI, alcohol consumption, comorbidities,
and/or concomitant drug therapy. Since information on
diseases and drug exposure was prospectively entered in
the General Practice Research Database in the absence
of any study hypothesis, recall bias is not an issue. Lastly,
exclusion of all patients with 3 years of recorded
history in the database prior to the index date reduced
the risk of including prevalent rather than incident gout
cases.
Some limitations of our study have to be ac-
knowledged. Misclassification of some gout cases may
have occurred, although previous studies (based on a
limited number of cases [i.e., 38]) have shown that gout
diagnoses are recorded with high validity in the General
Practice Research Database (38), and similar case defi-
nitions have been used in other studies (38,39). How-
ever, gout diagnoses are often made based on clinical
presentation and are rarely confirmed in routine clinical
practice by analysis of aspirated joint fluid for evidence
of urate crystals. To minimize misclassification, we ex-
cluded subjects with differential diagnoses such as os-
teoarthritis, arthropathy due to hemochromatosis, septic
arthritis, or rheumatoid arthritis that were recorded
around the index date. Nevertheless, misclassification
could, in theory, distort our findings toward the ob-
served increased risk of gout among users of different
diuretic drug classes through the introduction of a diag-
nostic bias (i.e., from a general practitioner who may be
aware of an association between use of diuretics and
gout). However, it is rather implausible that such a
diagnostic bias accounts for the substantially increased
relative risk estimates we observed. Furthermore, pres-
ence of such a bias would also be expected in individuals
who used potassium-sparing agents.
Residual confounding by indication by chronic
kidney disease and CHF, which are causally linked to
development of hyperuricemia, cannot be excluded in
the current study despite every effort to minimize such a
bias. Of note, we decided not to include these comor-
bidities in the final model due to concerns regarding
overadjustment (41). However, we adjusted for use of
drugs indicated for treatment of these comorbidities,
and we stratified our analyses by the most important
comorbidities, namely, arterial hypertension, chronic
kidney disease, and CHF. By including “past users” as
the reference group, we intended to further minimize
bias by indication.
We did not adjust for all potential risk factors
for gout, since, for example, dietary habits or physical
activities (2,5) are not routinely recorded in the General
Practice Research Database. However, we adjusted for
BMI, a factor that is related to physical activity and
194 BRUDERER ET AL
72
dietary habits. We were unable to assess race/ethnicity
because this information is also not consistently avail-
able in the General Practice Research Database. How-
ever, as 86% of individuals living in the UK are white
(42), our results are most likely representative of that
same demographic. Finally, we could not address poten-
tial confounding by socioeconomic status; however, we
partially controlled for this potential confounder by
matching cases and controls from the same general
practice, since it is likely that patients from the same
neighborhood see the same general practitioner. In
summary, this large observational study provides evi-
dence that current use of loop diuretics, thiazide diuret-
ics, and thiazide-like diuretics is associated with a sub-
stantially increased risk of incident gout.
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ABSTRACT
Objective The aim of this study was to explore the risk
of incident gout in patients with type 2 diabetes mellitus
(T2DM) in association with diabetes duration, diabetes
severity and antidiabetic drug treatment.
Methods We conducted a case-control study in
patients with T2DM using the UK-based Clinical Practice
Research Datalink (CPRD). We identified case patients
aged ≥18 years with an incident diagnosis of gout
between 1990 and 2012. We matched to each case
patient one gout-free control patient. We used
conditional logistic regression analysis to calculate
adjusted ORs (adj. ORs) with 95% CIs and adjusted our
analyses for important potential confounders.
Results The study encompassed 7536 T2DM cases
with a first-time diagnosis of gout. Compared to a
diabetes duration <1 year, prolonged diabetes duration
(1–3, 3–6, 7–9 and ≥10 years) was associated with
decreased adj. ORs of 0.91 (95% CI 0.79 to 1.04), 0.76
(95% CI 0.67 to 0.86), 0.70 (95% CI 0.61 to 0.86),
and 0.58 (95% CI 0.51 to 0.66), respectively. Compared
to a reference A1C level of <7%, the risk estimates of
increasing A1C levels (7.0–7.9, 8.0–8.9 and ≥9%)
steadily decreased with adj. ORs of 0.79 (95% CI 0.72
to 0.86), 0.63 (95% CI 0.55 to 0.72), and 0.46 (95%
CI 0.40 to 0.53), respectively. Neither use of insulin,
metformin, nor sulfonylureas was associated with an
altered risk of incident gout.
Conclusions Increased A1C levels, but not use of
antidiabetic drugs, was associated with a decreased risk
of incident gout among patients with T2DM.
INTRODUCTION
Gout is a common painful inflammatory arthritis
with acute onset, characterised by deposition of
monosodium urate crystals in affected joints.1 2 The
reported prevalence in the UK is about 1.4%.3
Increasing age and male gender,3 obesity,4 alcohol
intake,5 and hyperuricaemia1 6 are the most import-
ant risk factors for gout. Congestive heart failure
(CHF), chronic kidney disease (CKD), arterial hyper-
tension and various drug treatments, such as different
types of diuretics, are also associated with a markedly
increased risk of gouty arthritis.7 Diabetes mellitus is
a comorbid condition to CHF, CKD and arterial
hypertension, which has also been associated with an
increased risk of gout in several studies.3 8–11
However, confounding by these comorbidities and
concomitant drug treatments was not routinely con-
trolled in these studies3 8–11 which were mostly based
on a limited number of patients.8–11Of note, a recent
observational study from the UK found a decreased
gout risk in individuals with diagnosed type 2 dia-
betes mellitus (T2DM) as compared to diabetes-free
subjects.12 Relative risk estimates decreased with
increasing diabetes duration and were lower in
treated than in untreated patients with diabetes melli-
tus.12 It could not be determined from the informa-
tion provided whether the observed risks were
further modified by certain antidiabetic treatments or
by diabetes disease severity.12 We therefore con-
ducted an observational study in patients with
T2DM to explore the association between diabetes
duration, diabetes severity and use of different types
of antidiabetic drugs and the risk of developing inci-
dent gout in T2DM patients.
PATIENTS AND METHODS
Data source
The data were derived from the UK-based Clinical
Practice Research Datalink (CPRD) which was
established around 1987 and encompasses data
from 450 general practices, representative of the
UK population.13 14 The individuals enrolled in the
database are representative of the UK population
with regard to age, sex, geographic distribution and
annual turnover rate.3 15 16 General practitioners
have been trained to record medical information
for research purposes using standard software and
coding systems. The CPRD holds information
regarding patient demographics and characteristics,
lifestyle variables, such as Body Mass Index (BMI),
smoking status, and alcohol consumption, symp-
toms, medical diagnoses, referrals to consultants
and hospitalisations. The general practitioner gen-
erates drug prescriptions directly with the com-
puter using a coded drug dictionary. The database
has been described in detail elsewhere17 18 and has
been validated extensively.13 19–22 The CPRD has
been the source of numerous epidemiological
studies published in peer-reviewed journals, includ-
ing pharmacoepidemiological studies on gout using
similar case definitions.3 7 23 24 Gout diagnoses are
recorded with high validity in the CPRD.24 The
Independent Scientific Advisory Committee (ISAC)
for the Medicines and Healthcare products
Regulatory Agency (MHRA) database research
approved the study.
Study population
Case patients
Using READ codes, we identified all patients aged
18 years or older with a first-time diagnosis of gout
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between 1 January 1990 and end June 2012 and with an ante-
cedent history of T2DM based on READ codes; we refer to the
date of the first gout diagnosis as the ‘index date’.
Exclusion criteria
We excluded all cases with less than 3 years of recorded history
in the database prior to the index date, and all patients with any
recorded diagnosis of type 1 diabetes mellitus, cancer (except
non-melanoma skin cancer), or a HIV infection. Additionally, to
minimise the risk of misclassification of cases with incident
gout, we excluded all patients with other conditions associated
with joint inflammation, such as haemochromatosis, osteoarth-
ritis, septic arthritis, or rheumatoid arthritis within 180 days
preceding the index date, or within 90 days after the index date.
Similar case definitions of gout have been used or validated in
previous studies based on CPRD data.3 7 23 24
Control patients
From the base population of patients with a history of T2DM,
we identified at random one control patient with no evidence of
gout, per case patient. Control patients were matched to cases
on age (same year of birth), sex, BMI (max ±2.0 kg/m2), calen-
dar time (same index date), general practice and number of
years of active history in the CPRD prior to the index date. We
applied the same exclusion criteria to control patients as to case
patients.
Exposure
The exposures of interest in this study were diabetes severity,
duration and treatment. Diabetes severity was classified accord-
ing to A1C levels recorded within 365 days prior to the index
date (no A1C-level recorded, <7%, 7.0–7.9%, 8.0–8.9%,
≥9.0%). We defined diabetes duration as the time interval
between the date of the first recorded diagnosis of T2DM and
the index date by counting the number of days (<1, 1–3, 3–7,
7–10, >10 years). We assessed the use of different types of anti-
diabetic drugs based on prescriptions in the computer records.
Cases and controls were classified as current users if their last
prescription was within 180 days prior to the index date; or as
past users if their last prescription was more than 180 days prior
to the index date. We also classified them into the following
groups: insulin users, metformin users, and sulfonylureas users.
Due to the low number of users of other antidiabetic drugs, we
did not assess their use separately. The duration of antidiabetic
drug exposure was classified based on the number of recorded
prescriptions for these drugs prior to the index date into 1–19
prescriptions, 20–39 prescriptions, 40–59 prescriptions, or
≥60 prescriptions.
Covariates
We classified demographics and lifestyle factors, such as
smoking status (non-smoker, current, past or unknown), alcohol
consumption (never, current (1–9 units per week; 10–19 units
per week; ≥20 units per week, unknown), past, unknown), and
number of general practitioner visits ever (0–19, 20–39, ≥40)
prior to the index date in cases and controls, and assessed these
covariates as potential confounders. We further assessed for
cases and controls whether they had arterial hypertension,
CKD, CHF, ischaemic heart disease (IHD), transient ischaemic
attack/stroke, dyslipidemia, or diabetes-related complications,
such as diabetic nephropathy, diabetic neuropathy, or diabetic
angiopathy at any time prior to the index date.
Furthermore, we assessed the independent effects of current
(last prescription within 180 days prior to the index date) use of
certain drugs of interest such as diuretics (loop, thiazide and
thiazide-like, or potassium-sparing diuretics), β-blockers, ACE
inhibitors (ACE-Is), angiotensin II receptor blockers (ARBs),
calcium channel blockers (CCBs), organic nitrates, statins and
low-dose acetylsalicylic acid (ASA) prior to the index date, and
we assessed these covariates as potential confounders.
Sensitivity analyses
In a predefined sensitivity analysis, we additionally matched
cases and controls on diabetes duration (±1 year) to ensure that
cases and controls had an equal length of diabetes history and,
therefore, equal exposure opportunity. To further address the
impact of this potential exposure time-related bias on our
results, we assessed diabetes duration across different exposure
duration strata for all antidiabetic drugs under study. In another
sensitivity analysis we assessed the risk of gout in association
with A1C level stratified by diabetes duration to explore
whether increasing A1C levels, irrespective of diabetes duration,
were associated with an altered risk of gout. To assess whether
diabetes duration or A1C levels are potential mediators of the
association between antidiabetic drug use and the risk of gout,
we additionally matched on diabetes duration and A1C (±1%).
In another sensitivity analysis we only included patients with
incident diabetes mellitus and incident antidiabetic drug use to
address potential prevalent user bias. Finally, we restricted our
analyses to cases and their matched controls who were treated
with either non-steroidal anti-inflammatory drugs (NSAIDS),
colchicine, or uricosuric or uricostatic drugs within 7, 30 and
90 days after the index date, respectively, to decrease the risk of
possible outcome misclassification.
Statistical analysis
We conducted conditional logistic regression analyses using SAS
statistical software V.9.3 (SAS Institute, Cary, North Carolina,
USA) to calculate relative risk estimates as ORs with 95% CIs.
We performed a χ2 test for trend (p<0.05) for diabetes duration
and A1C levels. We explored the association between potential
risk factors and the risk for gout in univariate analyses. We
tested the effects of each of these potential confounders in
multivariate analyses and included them in the final model if
they altered the effect of antidiabetic drug use on the risk of
gout by more than 10%. We a priori decided to adjust the ana-
lysis of antidiabetic drug use for smoking status, alcohol con-
sumption, and number of general practitioner visits.
RESULTS
There were 7536 cases of incident gout in the T2DM study
population, matched to 7536 diabetic, but gout-free controls.
Of these, 62.5% were male, and the mean age (±SD) was 69.9
±11.0 years. Alcohol consumption was associated with an
increased risk of gout, while current smoking was associated
with a decreased risk. Comorbidities, such as arterial hyperten-
sion, CKD, CHF and IHD were all associated with an increased
risk of incident gout. The characteristics of cases and controls
are displayed in table 1.
Current use of most antihypertensive drugs except CCBs,
which was associated with a decreased adj. OR of 0.87 (95% CI
0.80 to 0.95), yielded increased relative risk estimates for inci-
dent gout (table 2).
The adjusted ORs for gouty arthritis in association with dur-
ation of T2DM of <1 (reference), 1–3, 3–7, 7–10 or >10 years
were 0.91 (95% CI 0.79 to 1.04), 0.76 (95% CI 0.67 to 0.86),
0.70 (95% CI 0.61 to 0.81), and 0.58 (95% CI 0.51 to 0.66),
respectively. Compared to a reference A1C level of <7%, the
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risk estimates of increasing A1C levels (7.0–7.9, 8.0–8.9 and
≥9%) steadily decreased with adj. ORs of 0.79 (95% CI 0.72 to
0.86), 0.63 (95% CI 0.55 to 0.72) and 0.46 (95% CI 0.40 to
0.53), respectively (table 3). Tests for trend were statistically sig-
nificant for prolonged diabetes duration and increasing A1C
levels. In the analysis where we stratified the A1C by diabetes
duration, increasing A1C levels were associated with a decreas-
ing relative risk estimate of gout irrespective of diabetes duration
(table 4).
Compared to non-use, current use of insulin, metformin and
sulfonylureas was associated with a decreased risk of developing
gout in the main analysis; however, we did not observe a
consistent duration effect (table 5). In this analysis, diabetes dur-
ation was closely similar (<3% difference) in cases and controls
among corresponding exposure duration for all antidiabetic
drugs studied (data not shown). In the sensitivity analysis where
we additionally matched on diabetes duration, relative risk esti-
mates were closely similar to the findings of the main analysis
(table 6). Finally, when we additionally matched our analyses on
A1C level, we did not observe decreased relative risk estimates
for use of any antidiabetic drugs (table 6).
In the sensitivity analyses in which we included patients with
incident diabetes mellitus and incident antidiabetic drug use
only and in which we restricted the population to gout patients
Table 1 Multivariable effects of various patient characteristics on the risk of gout in T2DM patients and matched controls
Variable Number of cases (%) (n=7536) Number of controls (%) (n=7536) OR crude (95% CI) OR adj.* (95% CI)
Sex†
Male 4712 (62.5) 4712 (62.5) NA NA
Female 2824 (37.5) 2824 (37.5) NA NA
Age group (years)†
30–39 61 (0.8) 51 (0.7) NA NA
40–49 311 (4.1) 313 (4.2) NA NA
50–59 947 (12.6) 944 (12.5) NA NA
60–69 2027 (26.9) 2057 (27.3) NA NA
70–79 2684 (35.6) 2712 (36.0) NA NA
≥80 1506 (20.0) 1459 (19.4) NA NA
BMI group (kg/m2)†
12.0–18.4 17 (0.2) 26 (0.4) NA NA
18.5–24.9 914 (12.1) 1043 (13.8) NA NA
25.0–29.9 2651 (35.2) 2731 (36.2) NA NA
30.0–60.0 3954 (52.5) 3736 (49.6) NA NA
Smoking status
Non-smoker 2747 (36.5) 3009 (39.9) 1 (reference) 1 (reference)
Current smoker 758 (10.1) 987 (13.1) 0.84 (0.75 to 0.94) 0.82 (0.72 to 0.92)
Ex-smoker 3912 (51.9) 3448 (45.8) 1.29 (1.19 to 1.38) 1.17 (1.08 to 1.27)
Unknown 119 (1.6) 92 (1.2) 1.40 (1.06 to 1.86) 1.57 (1.13 to 2.18)
Alcohol consumption (units/week)‡
Never/ex 1845 (24.5) 2021 (26.8) 1 (reference) 1 (reference)
Current unknown 1939 (25.7) 2061 (27.4) 1.04 (0.95 to 1.14) 1.06 (0.96 to 1.17)
Current 1–9 1821 (24.2) 1833 (24.3) 1.12 (1.02 to 1.23) 1.14 (1.02 to 1.26)
Current 10–19 736 (9.8) 612 (8.1) 1.40 (1.23 to 1.59) 1.56 (1.35 to 1.79)
Current ≥20 790 (10.5) 541 (7.2) 1.72 (1.50 to 1.97) 1.94 (1.68 to 2.25)
Unknown 405 (5.4) 468 (6.2) 0.95 (0.81 to 1.11) 1.01 (0.84 to 1.21)
General practitioner visits
0–19 435 (5.8) 443 (5.9) 1 (reference) 1 (reference)
20–39 697 (9.3) 843 (11.2) 0.85 (0.72 to 1.01) 0.73 (0.61 to 0.88)
≥40 6404 (85.0) 6250 (82.9) 1.12 (0.96 to 1.31) 0.78 (0.66 to 0.93)
Comorbidities
Diabetic angiopathy 23 (0.3) 17 (0.2) 1.35 (0.72 to 2.53) 1.31 (0.64 to 2.70)
Diabetic nephropathy 425 (5.6) 334 (4.4) 1.30 (1.12 to 1.52) 1.07 (0.90 to 1.26)
Diabetic neuropathy 249 (3.3) 259 (3.4) 0.96 (0.80 to 1.15) 0.85 (0.70 to 1.03)
Hypertension 5658 (75.1) 4971 (66.0) 1.63 (1.51 to 1.76) 1.58 (1.46 to 1.72)
Dyslipidemia 2569 (34.1) 2282 (30.3) 1.21 (1.12 to 1.30) 1.06 (0.98 to 1.15)
Chronic kidney disease 3176 (42.1) 2234 (29.6) 2.78 (2.52 to 3.07) 2.36 (2.12 to 2.62)
Congestive heart failure 1478 (19.6) 493 (6.5) 3.62 (3.23 to 4.06) 3.04 (2.69 to 3.43)
Ischaemic heart disease 2798 (37.1) 1945 (25.8) 1.73 (1.61 to 1.86) 1.38 (1.27 to 1.50)
Stroke/TIA 1015 (13.5) 799 (10.6) 1.33 (1.20 to 1.47) 1.13 (1.01 to 1.26)
*Adjusted for: smoking status, alcohol consumption, general practitioner visits, hypertension, dyslipidemia, chronic kidney disease, congestive heart failure, ischaemic heart disease,
stroke/TIA.
†Matching variables age, sex, BMI, general practice, history in the database and index date.
‡1U (Unit)=10 mL of pure ethanol (8 g of ethanol).
BMI, Body Mass Index; NA: not applicable; TIA, transient ischaemic attack; T2DM, type 2 diabetes mellitus.
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treated with NSAIDs, colchicine, uricosuric or uricostatic drugs,
results did not materially differ from the main analysis (data not
shown).
DISCUSSION
In this large observational study using the UK-based CPRD, we
found a markedly decreased risk of incident gout among
patients with increasing levels of A1C compared to patients
with an A1C level <7%. The risk of gout was also decreased in
association with increasing diabetes duration, a finding which is
consistent with reported results of a recent population-based
study in UK patients using the health improvement network
database (THIN).12 Of interest, when we assessed the risk of
gout in association with different A1C levels stratified by dia-
betes duration, increasing A1C levels irrespective of diabetes
duration were associated with a decreased risk of gout. We are
not aware of another observational study exploring the associ-
ation between A1C as the surrogate marker for disease severity
of T2DM and the risk of incident gout. Of note, Choi and
Ford,25 using the US Third National Health and Nutrition
Examination Survey (1988–1994), explored the association
between A1C levels and serum uric acid levels, an important
risk factor for gouty arthritis. Interestingly, they found that sub-
jects with an A1C level of 6.0–6.9% had increased serum uric
acid levels compared to patients with lower A1C levels.
However, in patients with diagnosed diabetes mellitus and/or
markedly increased A1C levels, they reported substantially
decreased uric acid levels. The authors finally concluded that
individuals with diabetes mellitus and markedly elevated A1C
levels may be at a lower risk of hyperuricaemia and gout.25
Possible mechanistic explanations for this observed association
include an uricosuric effect of glycosuria 25–27 or an impaired
inflammatory response in patients with severe and long-lasting
diabetes mellitus.1 By contrast with our findings, and arguing
against the proposed mechanisms discussed above, several small
observational studies suggested an increased risk of gout in
patients with T2DM.8–11 Two studies from Taiwan 9 10 explored
the association between gout and manifestations of the meta-
bolic syndrome9 and trends in the manifestation of gout10 using
a hospital-derived database. They found an increased risk of
Table 2 ORs (current use vs non-use) for co-medications in relation to the risk of gout
Co-medication Number of cases (%) (n=7536) Number of controls (%) (n=7536) OR crude (95% CI) OR adj.* (95% CI)
ACE-Is 3946 (52.4) 3303 (43.8) 1.81 (1.68 to 1.96) 1.35 (1.24 to 1.48)
ARBs (excl. losartan) 1027 (13.6) 757 (10.1) 1.50 (1.35 to 1.66) 1.26 (1.12 to 1.41)
Losartan 353 (4.7) 292 (3.9) 1.25 (1.07 to 1.47) 1.06 (0.68 to 1.63)
Loop diuretics 2742 (36.4) 1103 (14.6) 3.81 (3.48 to 4.17) 3.07 (2.77 to 3.41)
Thiazide diuretics 1815 (24.1) 1445 (19.2) 1.51 (1.38 to 1.64) 1.74 (1.58 to 1.92)
Potassium sparing diuretics 584 (7.8) 163 (2.2) 3.97 (3.31 to 4.76) 2.34 (1.92 to 2.84)
β-blockers 2776 (36.8) 1984 (26.3) 1.86 (1.72 to 2.01) 1.51 (1.38 to 1.65)
Calcium channel blockers 2295 (30.5) 2371 (31.5) 1.16 (1.07 to 1.25) 0.87 (0.80 to 0.95)
Nitrates 1364 (18.1) 893 (11.9) 1.79 (1.63 to 1.98) 1.26 (1.12 to 1.41)
Statins 4679 (62.1) 4449 (59.0) 1.30 (1.19 to 1.41) 1.02 (0.92 to 1.12)
ASA low-dose 3370 (44.7) 3218 (42.7) 1.21 (1.12 to 1.30) 0.95 (0.87 to 1.04)
*Adjusted for: smoking status, alcohol consumption, general practitioner visits, ACE-Is, ARBs excl. losartan, losartan, loop diuretics, thiazide diuretics, potassium sparing diuretics,
β-blockers, calcium channel blockers, nitrates, statins, low dose ASA.
ACE-Is, ACE inhibitors; ARBs, angiotensin receptor blockers; ASA, acetylsalicylic acid.
Table 3 ORs for A1C levels and diabetes duration in relation to the risk of gout
Variable
Number of cases (%)
(n=7536)
Number of controls (%)
(n=7536) OR crude (95% CI) OR adj.* (95% CI)
Diabetes duration (years)
<1 909 (12.1) 721 (9.6) 1 (reference) 1 (reference)
1–3 1515 (20.1) 1334 (17.7) 0.90 (0.79 to 1.02) 0.91 (0.79 to 1.04)
3–7 2281 (30.3) 2289 (30.4) 0.78 (0.70 to 0.88) 0.76 (0.67 to 0.86)
7–10 1095 (14.5) 1166 (15.5) 0.73 (0.65 to 0.84) 0.70 (0.61 to 0.81)
>10 1736 (23.0) 2026 (26.9) 0.67 (0.59 to 0.75) 0.58 (0.51 to 0.66)
A1C level†
Unknown 798 (10.6) 718 (9.5) 0.97 (0.85 to 1.12) 1.01 (0.87 to 1.18)
<7% 3730 (49.5) 3186 (42.3) 1 (reference) 1 (reference)
7.0–7.9% 1858 (24.7) 1989 (26.4) 0.79 (0.74 to 0.86) 0.79 (0.72 to 0.86)
8.0–8.9% 636 (8.4) 795 (10.6) 0.67 (0.60 to 0.76) 0.63 (0.55 to 0.72)
≥9% 514 (6.8) 848 (11.3) 0.50 (0.45 to 0.57) 0.46 (0.40 to 0.53)
χ2 test for trend (p<0.05) was statistically significant for diabetes duration and A1C level.
*Adjusted for: smoking status, alcohol consumption, general practitioner visits, hypertension, dyslipidemia, chronic kidney disease, congestive heart failure, ischaemic heart disease,
stroke/TIA.
†A1C-level if a value was recorded within 1 year prior to the index date.
TIA, transient ischaemic attack.
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gout in patients with T2DM. However, the results were not
adjusted for important risk factors of gout and comorbid condi-
tions for T2DM.9 10 Comorbidities, such as arterial hyperten-
sion, CKD and CHF, as well as co-medications, such as different
types of diuretics, have been associated with a substantially
increased risk of gout in this study as well as in previous
studies,7 28 and could, therefore, explain the positive associ-
ation. In two questionnaire-based studies, one from Greece11
and one from New Zealand,8 the authors reported increased
relative risks of gout in association with T2DM. Again, the
results were not adjusted for important confounders. Finally, in
a larger study using the General Practice Research Database
(former name for the CPRD), diabetes mellitus was associated
with a slightly increased risk for incident gout in univariate ana-
lysis.3 Again, no adjusted results for important confounders
were reported in that study.
In our study, increasing A1C levels were associated with a sig-
nificantly decreased risk of incident gout. While a uricosuric
effect of poorly controlled hyperglycaemia and/or impaired
inflammatory response in prolonged and poorly controlled dia-
betes offer potential mechanistic explanations for these find-
ings,1 25–27 a potential effect of antidiabetic drug treatment on
these risk estimates should also be considered. Rodriguez and
coworkers12 did not report detailed results, but observed that
relative risk estimates for incident gout were lower in patients
with treated T2DM compared to patients who did not receive
treatment. Whether this observation reflects a beneficial effect
of antidiabetic drug treatment or is explained by more severe
and/or prolonged diabetes mellitus remains unclear. In our
study, we did not find evidence that different types of antidia-
betic drugs alter the risk of gouty arthritis. Although we
observed marginally decreased relative risk estimates of gout in
current antidiabetic drug users in the main analysis, there was
no consistent trend with increasing number of prescriptions.
Finally, in the sensitivity analysis in which we explored the asso-
ciation between different antidiabetic drugs and gout, which
was additionally matched on diabetes duration and A1C level,
current antidiabetic drug treatment was no more associated with
an altered risk of gout, irrespective of the specific drug used.
Taken together, our results strongly suggest that increasing A1C
levels, but not prolonged diabetes duration, per se, nor different
antidiabetic drug treatments, explain the observed decreased
relative risk estimates of gout.
This large population-based study has several strengths. First,
the diagnosis of gout has been validated in this well-established
primary care database,3 24 and similar case definitions for
Table 4 Risk of gout in association with A1C stratified by diabetes duration
Variable
Number of cases
n=7536 (%)
Number of controls
n=7536 (%) OR crude (95% CI) OR adj.* (95% CI)
<1 year
Unknown 228 (3.0) 154 (2.0) 1.11 (0.86 to 1.44) 1.02 (0.77 to 1.35)
<7% 428 (5.7) 324 (4.3) 1 (reference) 1 (reference)
7.0–7.9% 163 (2.2) 131 (1.7) 0.95 (0.73 to 1.25) 1.06 (0.79 to 1.43)
8.0–8.9% 40 (0.5) 45 (0.6) 0.67 (0.42 to 1.05) 0.71 (0.44 to 1.17)
≥9% 50 (0.7) 67 (0.9) 0.57 (0.38 to 0.84) 0.65 (0.42 to 1.00)
1–3 years
Unknown 155 (2.1) 136 (1.8) 0.92 (0.70 to 1.20) 0.92 (0.69 to 1.24)
<7% 905 (12.0) 715 (9.5) 1 (reference) 1 (reference)
7.0–7.9% 338 (4.5) 310 (4.1) 0.85 (0.71 to 1.02) 0.86 (0.70 to 1.05)
8.0–8.9% 67 (0.9) 94 (1.3) 0.54 (0.39 to 0.76) 0.51 (0.35 to 0.73)
≥9% 50 (0.7) 79 (1.1) 0.48 (0.33 to 0.70) 0.55 (0.37 to 0.83)
3–7 years
Unknown 196 (2.6) 186 (2.5) 0.93 (0.73 to 1.20) 1.01 (0.77 to 1.33)
<7% 1206 (16.0) 1062 (14.1) 1 (reference) 1 (reference)
7.0–7.9% 607 (8.1) 608 (8.1) 0.88 (0.77 to 1.02) 0.97 (0.83 to 1.13)
8.0–8.9% 149 (2.0) 219 (2.9) 0.59 (0.47 to 0.74) 0.66 (0.52 to 0.85)
≥9% 123 (1.6) 214 (2.8) 0.49 (0.39 to 0.63) 0.53 (0.40 to 0.69)
7–10 years
Unknown 76 (1.0) 78 (1.0) 0.85 (0.60 to 1.21) 0.87 (0.59 to 1.29)
<7% 528 (7.0) 465 (6.2) 1 (reference) 1 (reference)
7.0–7.9% 277 (3.7) 331 (4.4) 0.73 (0.60 to 0.90) 0.78 (0.62 to 0.98)
8.0–8.9% 133 (1.8) 142 (1.9) 0.80 (0.61 to 1.05) 0.78 (0.57 to 1.05)
≥9% 81 (1.1) 150 (2.0) 0.44 (0.33 to 0.60) 0.44 (0.31 to 0.61)
>10 years
Unknown 143 (1.9) 164 (2.2) 0.82 (0.62 to 1.07) 0.83 (0.62 to 1.12)
<7% 663 (8.8) 620 (8.2) 1 (reference) 1 (reference)
7.0–7.9% 473 (6.3) 609 (8.1) 0.72 (0.61 to 0.85) 0.72 (0.60 to 0.87)
8.0–8.9% 247 (3.3) 295 (3.9) 0.78 (0.64 to 0.96) 0.70 (0.55 to 0.88)
≥9% 210 (2.8) 338 (4.5) 0.58 (0.47 to 0.71) 0.51 (0.40 to 0.64)
*Adjusted for: smoking status, alcohol consumption, general practitioner visits, ACE-Is, ARBs excl. losartan, losartan, loop diuretics, thiazide diuretics, potassium sparing diuretics,
β-blockers, calcium channel blockers, nitrates, statins, low-dose ASA, and antidiabetic drugs.
ACE-Is, ACE inhibitors; ARBs, angiotensin receptor blockers; ASA, acetylsalicylic acid.
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incident gout have been used by other authors.3 7 23 24 Second,
we were in the position to study a large number of cases with
T2DM and incident gout, to explore the role of duration and
severity of T2DM, and to run various sensitivity analyses to
address in-depth the potential role of different antidiabetic treat-
ments on the risk of incident gout. Third, unlike in most former
studies, we were able to address the role of important potential
confounders such as age, sex and BMI by matching, and we
adjusted our analyses for various important comorbidities and
co-medications. Fourth, information in the CPRD is prospect-
ively collected in the absence of any study hypothesis; therefore,
recall bias is not an issue in this study. Fifth, exclusion of
patients with less than 3 years of recorded history in the CPRD
prior to the index date reduced the likelihood of including
prevalent rather than incident gout cases. Finally, time-related
biases, namely bias by different exposure opportunity (also
named ‘time-window bias’) and immortal time bias were likely
not an issue in this study in which we explored potential drug
effects on the risk of incident gout. Furthermore, our findings
were closely similar in the sensitivity analysis in which we
matched cases and controls on diabetes duration.
Potential limitations of this study are possible misclassification
of some gout cases, since diagnoses were mainly made by
general practitioners, and not all by rheumatologists. However,
a previous study has shown that gout diagnoses are recorded
with high validity in the CPRD,24 and other investigators used
similar case definitions.7 23 24 Furthermore, we excluded sub-
jects with recorded differential diagnoses of gout, such as osteo-
arthritis, septic arthritis, arthropathy due to haemochromatosis,
or rheumatoid arthritis to reduce the risk of misclassification.
Furthermore, we were not able to adjust for all potential risk
factors for gouty arthritis since dietary habits and physical activ-
ity 1 4 are not routinely recorded in the CPRD. However, by
matching on BMI which is related to physical activity and
dietary habits, we partly controlled for these risk factors.
Additionally, we were not able to address potential confounding
by socioeconomic status in-depth. However, we partially con-
trolled for it by matching cases and controls on general practice
attended, as it is likely that patients from the same neighbour-
hood see the same general practitioner. Finally, we were unable
to assess race/ethnicity because this information is not consist-
ently available in the CPRD. Our results are most likely repre-
sentative of Caucasians, since 86% of individuals living in the
UK are white.29
In summary, this large observational study provides evidence
that increasing A1C levels are associated with a markedly
Table 5 ORs for duration of use of different antidiabetic drugs among cases with incident gout and matched controls
Variable
Number of cases (%)
(n=7536)
Number of controls (%)
(n=7536) OR crude (95% CI) OR adj.* (95% CI)
Insulin
Never used 6606 (87.7) 6600 (87.6) 1 (reference) 1 (reference)
Current use (<180 days)
Overall 868 (11.5) 878 (11.7) 0.99 (0.89 to 1.09) 0.74 (0.65 to 0.85)
1–19 prescriptions 316 (4.2) 269 (3.6) 1.17 (0.99 to 1.38) 0.96 (0.79 to 1.17)
20–39 prescriptions 196 (2.6) 224 (3.0) 0.87 (0.72 to 1.06) 0.67 (0.53 to 0.85)
40–59 prescriptions 118 (1.6) 138 (1.8) 0.86 (0.67 to 1.10) 0.62 (0.46 to 0.82)
≥60 prescriptions 238 (3.2) 247 (3.3) 0.97 (0.81 to 1.16) 0.63 (0.50 to 0.79)
Past use
Overall 62 (0.8) 58 (0.8) 1.07 (0.75 to 1.53) 0.91 (0.61 to 1.36)
Metformin
Never used 3284 (43.6) 2812 (37.3) 1 (reference) 1 (reference)
Current use (<180 days)
Overall 3218 (42.7) 3896 (51.7) 0.68 (0.64 to 0.74) 0.71 (0.65 to 0.77)
1–19 prescriptions 1197 (15.9) 1331 (17.7) 0.74 (0.68 to 0.82) 0.75 (0.67 to 0.83)
20–39 prescriptions 789 (10.5) 990 (13.1) 0.66 (0.59 to 0.73) 0.67 (0.59 to 0.76)
40–59 prescriptions 516 (6.9) 663 (8.8) 0.64 (0.57 to 0.73) 0.70 (0.60 to 0.81)
≥60 prescriptions 716 (9.5) 912 (12.1) 0.65 (0.58 to 0.73) 0.71 (0.62 to 0.82)
Past use
Overall 1034 (13.7) 828 (11.0) 1.03 (0.92 to 1.15) 0.91 (0.80 to 1.04)
Sulfonylurea
Never used 4239 (56.3) 3881 (51.5) 1 (reference) 1 (reference)
Current use (<180 days)
Overall 2389 (31.7) 2708 (35.9) 0.80 (0.75 to 0.86) 0.82 (0.75 to 0.89)
1–19 prescriptions 823 (10.9) 863 (11.5) 0.87 (0.78 to 0.97) 0.88 (0.78 to 0.99)
20–39prescriptions 583 (7.7) 592 (7.9) 0.90 (0.79 to 1.01) 0.91 (0.79 to 1.04)
40–59prescriptions 374 (5.0) 477 (6.3) 0.72 (0.62 to 0.83) 0.75 (0.63 to 0.88)
≥60 prescriptions 609 (8.1) 776 (10.3) 0.71 (0.63 to 0.79) 0.71 (0.62 to 0.82)
Past use
Overall 908 (12.1) 947 (12.6) 0.88 (0.79 to 0.97) 0.88 (0.77 to 1.01)
*Adjusted for: smoking status, alcohol consumption, general practitioner visits, ACE-Is, ARBs excl. losartan, losartan, loop diuretics, thiazide diuretics, potassium sparing diuretics,
β-blockers, calcium channel blockers, nitrates, statins, low-dose ASA, and antidiabetic drugs.
ACE-Is, ACE inhibitors; ARBs, angiotensin receptor blockers; ASA, acetylsalicylic acid.
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decreased risk of incident gout in patients with T2DM. Neither
use of insulin, metformin, nor sulfonylureas was associated with
an altered risk of incident gout.
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ABSTRACT
Background and Objective
Gout risk increases after menopause. The role of female sex hormones and
of use of hormone replacement therapy (HRT) on the gout risk is not well
known.
Objective
To assess the risk of developing incident gout in association with use of
postmenopausal HRT, according to type, timing, duration, and route of HRT
administration.
Design and setting
Case-control analysis within the UK Clinical Practice Research Datalink
Participants
We identified 13,489 female patients aged ≥45 years with incident gout be-
tween 1990 and 2010. We excluded all cases with less than 3 years of recorded
history prior to the index date, with a diagnosis of human immunodeficiency
virus (HIV) or cancer (except non-melanoma skin cancer) prior to the in-
dex date, and women with a diagnosis of hemochromatosis, septic arthritis,
rheumatoid arthritis, or osteoarthritis. We identified at random one female
control for each case, matched on age, general practice, calendar time, and
years of active history in the database, and applied the same exclusion criteria
to controls as to cases.
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Main outcome measures
Odds ratios (ORs) with 95% confidence intervals (CIs)
Results
Adjusted ORs of gout for current use of oral formulations of opposed oestro-
gens (oestrogen plus progesterone) were 0.69 (95% CI 0.56 to 0.86) compared to
never use. Current use was associated with a decreased risk of gout in patients
without renal failure (adj. OR 0.71, 95% CI 0.57 to 0.87) and hypertension
(adj. OR 0.62, 95% CI 0.44 to 0.87) compared to never use. Oestrogens alone
did not alter the gout risk.
Conclusions
Current use of oral opposed, but not of unopposed oestrogens was associ-
ated with a decreased risk of incident gout in patients without renal failure,
and it was more pronounced in patients with hypertension. The decreased
gout risk associated with HRT use may be related to the progesterone rather
than the oestrogen component.
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INTRODUCTION
Gouty arthritis is a common painful inflammatory arthritis with acute on-
set, characterized by deposition of monosodium urate crystals in affected joints
and surrounding tissue (1, 2). Older age, male gender, hyperuricemia, obesity,
and alcohol are important risk factors for gout (3, 4). Furthermore, arterial
hypertension, renal failure, congestive heart failure, and use of diuretics or an-
tihypertensive drugs have also been associated with an increased risk of gout
(5, 6).
The incidence of gout differs between males and females and is strongly
related to age in females (7, 8). Gouty arthritis is rarely diagnosed in pre-
menopausal women, but gout incidence and prevalence increase after menopause
(7-9). Several authors demonstrated that urate levels, an important risk factor
for gout, substantially increase with age in women, but not in men (10-12).
This led to the notion that changes in serum levels of female sex hormones
after menopause may be linked to increasing urate levels and to an increased
gout risk (13-15), and that female sex hormones may protect against the devel-
opment of gouty arthritis (7, 16-18). Indeed, investigations showed that both
oestrogen and progesterone stimulate renal clearance of uric acid and thereby
decrease serum urate levels (11, 12). Furthermore, postmenopausal hormone
replacement therapy (HRT) was shown to also reduce serum uric acid levels
(19, 20). Finally, postmenopausal HRT use was associated with a modestly
reduced gout risk in one published study (9), but the investigators did not
report details of dose, duration, or route of HRT administration or on possible
differences between use of oestrogens alone versus use of opposed oestrogens,
i.e. oestrogens plus progesterone.
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HRT is licensed for relief of climacteric symptoms and for the prophylaxis
of osteoporosis in peri- and postmenopausal women (21). Women with in-
tact uteri usually take combination oestrogen and progesterone therapy, while
women with prior hysterectomy may receive unopposed oestrogens (21). We
conducted a large case-control analysis using a well validated primary care
database to explore the risk of gout development in association with HRT use,
with detailed analyses on the type of HRT, timing and duration of use and
route of administration.
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METHODS
Data source
We derived data from the United Kingdom (UK)-based Clinical Practice
Research Datalink (CPRD), a large primary care database which was estab-
lished in 1987 and encompasses data from some 450 general practices on some 7
million patients who are representative of the UK population (22, 23) with re-
gard to age, sex, geographic distribution, and annual turnover rate (7, 24, 25).
The CPRD holds information regarding patient demographics and character-
istics, lifestyle variables such as body mass index (BMI), smoking status, and
alcohol consumption, symptoms, medical diagnoses, referrals to consultants,
and hospitalizations. The general practitioners generate drug prescriptions
directly with the computer using a coded drug dictionary. The database has
been described in detail (26, 27) and has been validated extensively (23, 28-31).
The CPRD has been the source of numerous epidemiological studies published
in peer-reviewed journals, including research on gout (6-8, 32, 33).
Study population
Case patients
Based on Read codes we identified in the CPRD female patients aged ≥45
years who had a first-time diagnosis of gout recorded between 1990 and 2010.
The date of the first diagnosis of gout was referred to as the index date. We
excluded all cases with less than three years of recorded history prior to the
index date in order to reduce the likelihood of including prevalent gout cases.
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We further excluded all patients with a diagnosis of human immunodeficiency
virus (HIV) or cancer (except non-melanoma skin cancer) prior to the index
date, as well as those with a diagnosis of hemochromatosis, septic arthritis,
rheumatoid arthritis, or osteoarthritis at any time within their record (to re-
duce the risk of misclassification, i.e. inclusion of gout cases who in fact had
another disease with similar symptoms). The diagnosis of gout in the CPRD
has been validated in a previous study (32) in which the authors used similar
case definitions (6-8, 33).
Control patients
We identified at random from the CPRD a control group of female patients
without evidence of gout. We applied the same exclusion criteria to controls
as to cases. We matched controls 1:1 to cases on age, general practice, number
of years of previous recorded history in the database, and index date.
Definition and classification of HRT use
We identified HRT prescriptions prior to the index date and classified ex-
posed patients into current users (last prescription ending <90 days prior to
the index date), past users (last prescription ending ≥90 days prior to the
index date), or never users. We determined a cut-off of 90 days for current
use because this is the typical maximal length of a prescription in the UK. We
further classified HRT users according to duration of use, taking the number of
HRT prescriptions (1−9, 10−19, ≥20 prescriptions) prior to the index date as
a proxy for treatment duration. In addition, we distinguished between opposed
(oestrogen plus progesterone) and unopposed (oestrogen only) HRT prescrip-
tions, and ran stratified analyses by route of administration (oral, transdermal
patch, vaginal, or else, including gel, implant, nasal, and injection).
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Covariates
We classified cases and controls according to their BMI (12.0−18.4, 18.5−
24.9, 25.0−29.9, 30.0−34.9, 35.0−39.9, 40.0−44.9, ≥45.0 kg/m2, or unknown),
smoking status (non-smoker, current smoker, ex-smoker, or unknown), alcohol
consumption (never, current [1−9 units per week; 10−19 units per week; ≥20
units per week], past, or unknown), and number of general practitioner visits
within the year immediately preceding the index date (0−2, 3−4, 5−9, ≥10
visits/year).
We assessed whether cases and controls had a recording of hysterectomy, os-
teoporosis, hypertension, renal failure, ischemic heart disease, congestive heart
failure, transient ischemic attack or stroke, diabetes mellitus, or dyslipidaemia
at any time prior to the index date. Furthermore, we assessed the association
between use of antihypertensive drugs (beta-blockers, angiotensin-converting-
enzyme inhibitors, angiotensin receptor blockers, or calcium channel blockers,
organic nitrates), statins, and low dose acetylsalicylic acid within 180 days
prior to the index date and gout. A cut-off of 180 days was chosen in order
to better distinguish between current and past users since these substances
are prescribed for long-term use, and many of these drugs are also available in
packages containing >90 tablets.
Statistical analysis
We conducted multivariate conditional logistic regression analyses to com-
pare the exposure prevalence of HRT between cases and controls. We present
relative risk estimates as odds ratios (ORs) with 95% confidence intervals (CIs),
and we considered a 2-sided p-value of <0.05 statistically significant. We con-
ducted the statistical analysis using the software program SAS, Version 9.3
(SAS institute, Inc., Cary, North Carolina).
When we analysed the exposure odds, we adjusted for patient characteris-
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tics, comorbidities or concomitant drug use in the multivariate analysis if these
potential confounders were predictor variables for gout known a priori from the
literature; these were BMI, smoking status, alcohol consumption, and general
practitioner visits within the last year preceding the index date for all analyses.
When we explored the association between incident gout and baseline charac-
teristics including life style factors (alcohol consumption and smoking status)
and different comorbidities, we additionally adjusted our analyses for hysterec-
tomy status (yes/no), and for the comorbidities hypertension, congestive heart
failure, ischemic heart disease, and renal failure. For all other analyses we si-
multaneously adjusted for use of diuretic and antihypertensive drugs, nitrates,
statins, low dose acetylsalicylic acid, and opposed or unopposed oestrogen.
Sensitivity analyses
We conducted various sensitivity analyses. First, we assessed the risk of
gout in association with use of HRT in the subset of cases (and their matched
controls) who were treated with either non-steroidal anti-inflammatory drugs
(NSAIDs), colchicine, and/or corticosteroids within 7 days, or uricosuric/urico-
static drugs within 90 days prior to or after the index date. This was done to
reduce the risk of misclassification, i.e. to increase the likelihood of including
valid gout cases. In a second sensitivity analysis, we excluded patients with a
history of renal failure, congestive heart failure, or hypertension to eliminate
residual confounding by these important risk factors for gout. In a third sen-
sitivity analysis, we stratified the study population by the presence or absence
of these comorbidities. In a fourth sensitivity analysis, we stratified the study
population by hysterectomy status, because increased gout risks have previ-
ously been reported in younger females with natural or surgical menopause
(9). In a fifth sensitivity analysis, we compared current HRT users to the
reference group of past HRT users to limit the risk of potential confounding
by indication. In a sixth sensitivity analysis we restricted the data to incident
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users of HRT by excluding prevalent users to address potential prevalent user
bias; incident users were women without any prescriptions for opposed or un-
opposed oestrogens within the first year of their registered history. Finally,
we assessed the risk of gout (ever use compared to never use only) of HRT
stratified by different routes of administration.
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RESULTS
The study population encompassed 13,489 incident female gout cases ≥45
years of age and the same number of matched controls. Mean (± standard
deviation) age at the index date was 70 ± 12.3 years. Increasing BMI was
associated with a higher risk of gout, as was current alcohol consumption in
a dose-dependent manner. Comorbidities known to be associated with an
increased risk of gout, such as hypertension, renal failure, congestive heart
failure, and ischemic heart disease were all associated with an increased risk
of incident gout (Table 1).
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Table 1 Baseline characteristics of female incident gout cases and matched
controls
Variable 
No. of cases 
(%) 
(n=13,489) 
No. of controls 
(%) (n=13,489) 
OR crude (95% CI) OR adj.* (95% CI) 
Age-group [years]° 
    
        
  45-49 786 (5.8) 786 (5.8) NA NA 
  50-54 984 (7.3) 988 (7.3) NA NA 
  55-59 1264 (9.4) 1256 (9.3) NA NA 
  60-64 1442 (10.7 1440 (10.7) NA NA 
  65-69 1304 (9.7) 1319 (9.8) NA NA 
  70-74 1527 (11.3 1525 (11.3) NA NA 
  75-79 1600 (11.9 1609 (11.9) NA NA 
  ≥80 4582 (34.0 4566 (33.9) NA NA 
BMI-group [kg/m2] 
        
  12.0-18.4 165 (1.2) 303 (2.3) 0.80 (0.66 - 0.98) 0.78 (0.62 - 0.98) 
  18.5-24.9 2871 (21.3 4386 (32.5) 1.00 (referent) 1.00 (referent) 
  25.0-29.9 3772 (28.0 3300 (24.5) 1.83 (1.71 - 1.96) 1.58 (1.46 - 1.71) 
  30.0-34.9 2422 (18.0 1276 (9.5) 3.23 (2.95 - 3.53) 2.50 (2.27 - 2.77) 
  35.0-39.9 1054 (7.8) 390 (2.9) 4.51 (3.95 - 5.15) 3.20 (2.76 - 3.71) 
  40.0-44.9 410 (3.0) 97 (0.7) 7.30 (5.75 - 9.26) 4.78 (3.69 - 6.20) 
  ≥45.0 214 (1.6) 41 (0.3) 8.95 (6.34 - 12.64) 5.17 (3.58 - 7.49) 
  Unknown 2581 (19.1 3696 (27.4) 0.88 (0.82 - 0.96) 1.33 (1.19 - 1.49) 
Smoking status 
        
  Non-smoker 6521 (48.3 6698 (49.7) 1.00 (referent) 1.00 (referent) 
  Current smoker 1726 (12.8 1802 (13.4) 0.99 (0.91 - 1.07) 1.21 (1.11 - 1.33) 
  Ex-smoker 3682 (27.3 2547 (18.9) 1.57 (1.48 - 1.68) 1.30 (1.20 - 1.40) 
  Unknown 1560 (11.6 2442 (18.1) 0.54 (0.49 - 0.58) 1.15 (1.01 - 1.32) 
Alcohol consumption [Units/week]§ 
      
  Never / Ex 3016 (22.4 2750 (20.4) 1.00 (referent) 1.00 (referent) 
  Current unknown 3146 (23.3 2936 (21.8) 0.98 (0.91 - 1.06) 1.05 (0.96 - 1.15) 
  Current 1-9 3238 (24.0 3160 (23.4) 0.95 (0.88 - 1.03) 1.13 (1.04 - 1.24) 
  Current 10-19 1045 (7.8) 818 (6.1) 1.21 (1.08 - 1.35) 1.59 (1.39 - 1.81) 
  Current >20 501 (3.7) 261 (1.9) 1.80 (1.54 - 2.12) 2.03 (1.68 - 2.46) 
  Unknown 2543 (18.9 3564 (26.4) 0.57 (0.53 - 0.62) 0.96 (0.85 - 1.09) 
General practitioner visits last year 
      
  0-2 1042 (7.7) 2976 (22.1) 1.00 (referent) 1.00 (referent) 
  3-4 407 (3.0) 864 (6.4) 1.39 (1.20 - 1.61) 1.21 (1.03 - 1.41) 
  5-9 1556 (11.5 2065 (15.3) 2.41 (2.17 - 2.68) 2.04 (1.81 - 2.29) 
  ≥10 10484 (77.7 7584 (56.2) 5.15 (4.71 - 5.64) 3.19 (2.87 - 3.53) 
Comorbidities  
        
  Hysterectomy 2882 (21.4 2337 (17.3) 1.32 (1.24 - 1.40) 1.18 (1.09 - 1.27) 
  Osteoporosis 817 (6.1) 894 (6.6) 0.91 (0.82 - 1.00) 0.93 (0.83 - 1.05) 
  Hypertension 8186 (60.7 4833 (35.8) 3.18 (3.00 - 3.36) 2.09 (1.95 - 2.23) 
  Diabetes mellitus 1721 (12.8 900 (6.7) 2.08 (1.91 - 2.27) 1.05 (0.94 - 1.16) 
  Dyslipidaemia 2408 (17.9 1559 (11.6) 1.78 (1.65 - 1.91) 1.07 (0.98 - 1.17) 
  Renal failure 4689 (34.8 2583 (19.2) 4.44 (4.07 - 4.85) 2.39 (2.16 - 2.63) 
  Congestive heart failure 1646 (12.2 505 (3.7) 3.98 (3.56 - 4.45) 2.91 (2.57 - 3.31) 
  Ischemic heart disease 2544 (18.9 1308 (9.7) 2.27 (2.11 - 2.45) 1.42 (1.30 - 1.56) 
  Stroke/TIA 1292 (9.6) 905 (6.7) 1.51 (1.38 - 1.65) 1.14 (1.02 - 1.27) 
BMI, body mass index; CI, confidence interval; OR, odds ratio; TIA, transient ischemic attack 
°Matching variables age, sex, general practice, history on the database and index date  
§1U (Unit) = 10ml of pure ethanol (8g of ethanol) 
*Adjusted for: BMI category, smoking status, alcohol consumption, number of general 
practitioner visits within last year, hysterectomy, hypertension, renal failure, congestive heart 
failure, ischemic heart disease 
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Current use of most antihypertensive drugs except calcium channel block-
ers, which were associated with decreased gout risks, were associated with
increased risks of gout compared to never use of these drugs (Table 2).
Table 2 ORs for gout in current use of various medications compared to
never use of each medication in female gout cases and matched controls
Comedication 
No. of cases 
(%) 
(n=13,489) 
No. of 
controls (%) 
(n=13,489) 
OR crude (95% 
CI) 
OR adj.* (95% CI) 
ACE-Inhibitors 3606 (26.7) 1656 (12.3) 3.46 (3.21 - 3.72) 1.53 (1.40 - 1.68) 
ARBs (excl. Losartan) 1009 (7.5) 415 (3.1) 2.90 (2.56 - 3.28) 1.24 (1.06 - 1.45) 
Losartan 354 (2.6) 148 (1.1) 2.51 (2.07 - 3.05) 1.11 (0.69 - 1.77) 
Loop diuretics 3250 (24.1) 889 (6.6) 5.73 (5.23 - 6.29) 3.26 (2.92 - 3.63) 
Thiazide diuretics 3440 (25.5) 1778 (13.2) 2.78 (2.59 - 2.98) 1.89 (1.73 - 2.06) 
Potassium sparing diuretics 557 (4.1) 117 (0.9) 5.31 (4.31 - 6.54) 2.33 (1.84 - 2.94) 
Beta-blockers 3846 (28.5) 1790 (13.3) 3.06 (2.86 - 3.28) 1.83 (1.68 - 1.99) 
Calcium channel blockers 2500 (18.5) 1717 (12.7) 1.90 (1.77 - 2.05) 0.89 (0.82 - 0.98) 
Nitrates 1283 (9.5) 551 (4.1) 2.67 (2.40 - 2.97) 1.29 (1.13 - 1.47) 
Statins 3113 (23.1) 1768 (13.1) 2.45 (2.27 - 2.64) 1.15 (1.04 - 1.26) 
ASA low-dose 2857 (21.2) 1755 (13.0) 2.07 (1.92 - 2.22) 0.98 (0.89 - 1.07) 
*Adjusted for: body mass index category, smoking status, alcohol consumption, number of 
general practitioner visits within last year, hysterectomy, angiotensin-converting-enzyme 
inhibitors, angiotensin receptor blockers excl. losartan, losartan, loop diuretics, thiazide 
diuretics, potassium sparing diuretics, beta-blockers, calcium channel blockers, nitrates, statins, 
low dose acetylsalicylic acid, oestrogens opposed, oestrogens unopposed 
 
Compared to never use, current use of opposed oestrogens (adj. OR 0.72,
95% CI 0.59 to 0.88), but not unopposed oestrogens (adj. OR 1.21, 95% CI
0.98 to 1.48), was associated with a decreased risk of incident gout. Relative
risk estimates of gout did not materially change with increasing number of
prescriptions in users of opposed or unopposed oestrogens (Table 3).
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Table 3 ORs for current use of hormone replacement therapy compared to
never use in female gout cases and matched controls
Hormone 
replacement 
therapy 
No. of cases 
(%) (n=13489) 
No. of controls 
(%) (n=13489) 
OR crude (95% CI) OR adj.* (95% CI) 
Oestrogens opposed                 
Never use 11772 (87.3) 11623 (86.2) 1.00 (reference) 1.00 (reference) 
Current use 
        
Overall 267 (2.0) 332 (2.5) 0.78 (0.66 - 0.92) 0.72 (0.59 - 0.88) 
1-9 prescriptions 85 (0.6) 113 (0.8) 0.72 (0.54 - 0.97) 0.68 (0.49 - 0.95) 
10-19prescriptions 67 (0.5) 78 (0.6) 0.82 (0.59 - 1.15) 0.77 (0.52 - 1.14) 
≥20 prescriptions 115 (0.9) 141 (1.1) 0.79 (0.62 - 1.02) 0.72 (0.53 - 0.97) 
Past use 
        
Overall 1450 (10.8) 1534 (11.4) 0.92 (0.84 - 1.00) 0.88 (0.79 - 0.97) 
1-9 prescriptions 857 (6.4) 836 (6.2) 0.99 (0.90 - 1.10) 0.95 (0.83 - 1.07) 
10-19prescriptions 300 (2.2) 350 (2.6) 0.83 (0.71 - 0.98) 0.81 (0.67 - 0.98) 
≥20 prescriptions 293 (2.2) 348 (2.6) 0.81 (0.69 - 0.96) 0.77 (0.63 - 0.94) 
Oestrogens unopposed               
Never use 12021 (89.1) 12268 (91.0) 1.00 (reference) 1.00 (reference) 
Current use 
        
Overall 343 (2.5) 234 (1.7) 1.54 (1.30 - 1.83) 1.21 (0.98 - 1.48) 
1-9 prescriptions 84 (0.6) 59 (0.4) 1.49 (1.06 - 2.09) 1.28 (0.87 - 1.89) 
10-19prescriptions 80 (0.6) 54 (0.4) 1.54 (1.08 - 2.18) 1.24 (0.83 - 1.87) 
≥20 prescriptions 179 (1.3) 121 (0.9) 1.57 (1.23 - 1.99) 1.15 (0.87 - 1.53) 
Past use 
        
Overall 1125 (8.3) 987 (7.3) 1.19 (1.08 - 1.30) 1.02 (0.91 - 1.14) 
1-9 prescriptions 638 (4.7) 603 (4.5) 1.10 (0.98 - 1.23) 0.96 (0.84 - 1.11) 
10-19prescriptions 217 (1.6) 180 (1.3) 1.27 (1.04 - 1.55) 1.16 (0.91 - 1.48) 
≥20 prescriptions 270 (2.0) 204 (1.5) 1.38 (1.15 - 1.67) 1.09 (0.86 - 1.37) 
*Adjusted for: body mass index category, smoking status, alcohol consumption, number of 
general practitioner visits within last year, angiotensin-converting-enzyme inhibitors, 
angiotensin receptor blockers excl. losartan, losartan, loop diuretics, thiazide diuretics, 
potassium sparing diuretics, beta-blockers, calcium channel blockers, nitrates, statins, low 
dose acetylsalicylic acid, oestrogens opposed and oestrogens unopposed for each other 
 
Results from the sensitivity analysis restricted to pharmacologically treated
gout patients or to patients without evidence for renal failure, congestive heart
failure, or hypertension did not materially differ from the main analysis (data
not shown).
When we stratified our analysis by renal failure, current use of opposed
oestrogens was associated with a decreased risk of gout in patients without
renal failure compared to never use (adj. OR 0.71, 95% CI 0.57 to 0.87), while
in patients with renal failure no such association was found (adj. OR 0.99,
95% CI 0.53 to 1.86).
In the analysis stratified by hypertension, current use of opposed oestro-
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gens was associated with a stronger protective effect risk (adj. OR 0.62, 95%
CI 0.44 to 0.87) in patients with hypertension, while the association was closer
to the null in cases and controls without hypertension (adj. OR 0.80, 95%
CI 0.63 to 1.02) (Table 4). We could not stratify by presence or absence of
congestive heart failure as there were too few patients with the disease.
Table 4 ORs for use of hormone replacement therapy stratified by renal
failure and by hypertension in female gout cases and matched controls
with comorbidity prior to the index date without comorbidity prior to the index date 
 
No. of cases 
(%) (n=13489) 
No. of controls 
(%) (n=13489) 
OR crude (95% CI) 
OR* adjusted (95% 
CI) 
No. of cases 
(%) (n=13489) 
No. of controls 
(%) (n=13489) 
OR crude (95% CI) 
OR* adjusted (95% 
CI) 
Renal failure 4689 (34.8) 2583 (19.2)         8800 (65.2) 10906 (80.9)         
Opposed oestrogens                                  
Non-use 4252 (31.5) 2328 (17.3) 1.00 (reference) 1.00 (reference) 7520 (55.8) 9295 (68.9) 1.00 (reference) 1.00 (reference) 
Current use 40 (0.3) 21 (0.2) 0.91 (0.52 - 1.60) 0.99 (0.53 - 1.86) 227 (1.7) 311 (2.3) 0.80 (0.66 - 0.96) 0.71 (0.57 - 0.87) 
Past use 397 (2.9) 234 (1.7) 0.82 (0.68 - 0.98) 0.82 (0.66 - 1.02) 1053 (7.8) 1300 (9.6) 0.97 (0.88 - 1.07) 0.90 (0.80 - 1.01) 
Unopposed oestrogens                                  
Non-use 4250 (31.5) 2363 (17.5) 1.00 (reference) 1.00 (reference) 7771 (57.6) 9905 (73.4) 1.00 (reference) 1.00 (reference) 
Current use 46 (0.3) 18 (0.1) 1.05 (0.59 - 1.87) 1.30 (0.67 - 2.52) 297 (2.2) 216 (1.6) 1.68 (1.40 - 2.03) 1.23 (0.99 - 1.52) 
Past use 393 (2.9) 202 (1.5) 1.08 (0.89 - 1.31) 1.05 (0.84 - 1.30) 732 (5.4) 785 (5.8) 1.25 (1.12 - 1.40) 1.04 (0.91 - 1.19) 
Hypertension 8186 (60.7) 4833 (35.8)         5303 (39.3) 8656 (64.2)         
Opposed oestrogens                                  
Non-use 7290 (54.0) 4267 (31.6) 1.00 (reference) 1.00 (reference) 4482 (33.2) 7356 (54.5) 1.00 (reference) 1.00 (reference) 
Current use 104 (0.8) 79 (0.6) 0.65 (0.48 - 0.88) 0.62 (0.44 - 0.87) 163 (1.2) 253 (1.9) 0.92 (0.74 - 1.13) 0.80 (0.63 - 1.02) 
Past use 792 (5.9) 487 (3.6) 0.90 (0.79 - 1.02) 0.77 (0.66 - 0.89) 658 (4.9) 1047 (7.8) 1.00 (0.89 - 1.12) 1.00 (0.88 - 1.14) 
Unopposed oestrogens                                  
Non-use 7317 (54.2) 4391 (32.6) 1.00 (reference) 1.00 (reference) 4704 (34.9) 7877 (58.4) 1.00 (reference) 1.00 (reference) 
Current use 182 (1.4) 73 (0.5) 1.38 (1.03 - 1.84) 1.17 (0.84 - 1.61) 161 (1.2) 161 (1.2) 1.55 (1.23 - 1.96) 1.25 (0.96 - 1.62) 
Past use 687 (5.1) 369 (2.7) 1.15 (1.00 - 1.32) 0.95 (0.81 - 1.12) 438 (3.3) 618 (4.6) 1.23 (1.07 - 1.41) 1.14 (0.98 - 1.33) 
*Adjusted for: body mass index category, smoking status, alcohol consumption, number of general practitioner visits within last year, angiotensin-converting-enzyme 
inhibitors, angiotensin receptor blockers excl. losartan, losartan, loop diuretics, thiazide diuretics, potassium sparing diuretics, beta-blockers, calcium channel blockers, 
nitrates, statins, low dose acetylsalicylic acid, oestrogens opposed and oestrogens unopposed for each other 
 
In the analysis stratified by hysterectomy status (21.4% of cases and 17.3%
of controls had prior hysterectomy), current use of opposed oestrogens was
associated with a decreased risk (0.71, 95% CI 0.58 to 0.88) in patients with-
out prior hysterectomy, while no such association was found in patients with
recorded hysterectomy (data not shown).
To address potential bias by indication, we compared current use of op-
posed or unopposed oestrogens to past use of each, and observed findings
closely similar to those of the main model (data not shown). Finally, in the
analysis restricted to current incident users of HRT compared to non-users the
results were closely similar to the main findings (data not shown).
Ever use of norethisterone acetate and oestrogen, medroxyprogesterone ac-
etate and oestrogen, and tibolone were associated with a decreased risk for
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incident gout compared to never use of these drugs (Table 5).
Table 5 ORs for use of hormone replacement therapy stratified by proges-
terone component respectively by single substances in female gout cases and
matched controls
Opposed oestrogens 
No. of cases 
(%) (n=13489) 
No. of 
controls (%) 
(n=13489) 
OR crude (95% 
CI) 
OR* adjusted 
(95% CI) 
Non-use 11807 (87.5) 11652 (86.4) 1.00 (reference) 1.00 (reference) 
Ever use by substance 
        
Dydrogesterone and oestrogen 65 (0.5) 70 (0.5) 0.90 (0.63 - 1.27) 0.97 (0.63 - 1.48) 
Levonorgestrel and oestrogen 87 (0.6) 95 (0.7) 0.89 (0.66 - 1.19) 0.77 (0.55 - 1.10) 
Norethisterone and oestrogen 607 (4.5) 671 (5.0) 0.88 (0.78 - 0.99) 0.81 (0.70 - 0.94) 
Medroxyprogesterone acetat 
and oestrogen 
199 (1.5) 251 (1.9) 0.77 (0.63 - 0.93) 0.69 (0.54 - 0.87) 
Norgestrel and oestrogen 439 (3.3) 429 (3.2) 0.99 (0.86 - 1.14) 0.98 (0.83 - 1.17) 
Raloxifen 35 (0.3) 39 (0.3) 0.88 (0.55 - 1.39) 1.23 (0.69 - 2.17) 
Tibolone 250 (1.9) 282 (2.1) 0.86 (0.72 - 1.02) 0.77 (0.63 - 0.95) 
*Adjusted for: body mass index category, smoking status, alcohol consumption, number of general 
practitioner visits within last year, angiotensin-converting-enzyme inhibitors, angiotensin receptor 
blockers excl. losartan, losartan, loop diuretics, thiazide diuretics, potassium sparing diuretics, beta-
blockers, calcium channel blockers, nitrates, statins, low dose acetylsalicylic acid, oestrogens 
unopposed 
 
Current use of oral opposed oestrogen preparations, but not of other routes
of administration, was associated with a significantly decreased risk of incident
gout (adj. OR 0.69, 95% CI 0.56 to 0.86). Further results are displayed in
Table 6.
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Table 6 ORs for current use of hormone replacement therapy compared to
never use, stratified by route of administration in female incident gout cases
and matched controls
Hormone 
replacement 
therapy 
No. of cases 
(%) (n=13489) 
No. of controls 
(%) (n=13489) 
OR crude (95% CI) 
OR* adjusted (95% 
CI) 
Opposed oestrogens  
       
Never use 11772 (87.3) 11623 (86.2) 1.00 (reference) 1.00 (reference) 
Current use by route of administration 
     
Patch 24 (0.2) 28 (0.2) 0.82 (0.47 - 1.43) 0.95 (0.50 - 1.82) 
Oral 236 (1.8) 298 (2.2) 0.77 (0.64 - 0.91) 0.69 (0.56 - 0.86) 
Past use by route of administration 
      
Patch 109 (0.8) 111 (0.8) 0.95 (0.73 - 1.24) 0.83 (0.60 - 1.16) 
Oral 1292 (9.6) 1378 (10.2) 0.91 (0.83 - 0.99) 0.88 (0.79 - 0.98) 
Else 56 (0.4) 51 (0.4) 1.07 (0.73 - 1.57) 1.03 (0.64 - 1.65) 
Unopposed oestrogens  
       
Never use 12021 (89.1) 12268 (91.0) 1.00 (reference) 1.00 (reference) 
Current use by route of administration 
     
Patch 73 (0.5) 62 (0.5) 1.27 (0.91 - 1.79) 1.02 (0.68 - 1.53) 
Oral 216 (1.6) 124 (0.9) 1.85 (1.47 - 2.33) 1.37 (1.05 - 1.78) 
Vaginal 37 (0.3) 34 (0.3) 1.10 (0.69 - 1.75) 0.87 (0.49 - 1.53) 
Else 17 (0.1) 14 (0.1) 1.27 (0.62 - 2.57) 1.39 (0.63 - 3.10) 
Past use by route of administration 
      
Patch 320 (2.4) 267 (2.0) 1.25 (1.06 - 1.48) 0.98 (0.79 - 1.20) 
Oral 536 (4.0) 423 (3.1) 1.32 (1.15 - 1.50) 1.17 (0.99 - 1.37) 
Vaginal 189 (1.4) 243 (1.8) 0.80 (0.66 - 0.97) 0.75 (0.59 - 0.95) 
Else 80 (0.6) 54 (0.4) 1.56 (1.10 - 2.21) 1.32 (0.86 - 2.02) 
*Adjusted for: body mass index category, smoking status, alcohol consumption, number of 
general practitioner visits within last year, angiotensin-converting-enzyme inhibitors, 
angiotensin receptor blockers excl. losartan, losartan, loop diuretics, thiazide diuretics, 
potassium sparing diuretics, beta-blockers, calcium channel blockers, nitrates, statins, low dose 
acetylsalicylic acid, oestrogens unopposed 
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DISCUSSION
In this large population-based case-control study, current use of opposed,
but not unopposed oestrogens was associated with a decreased risk of incident
gout (adj. OR 0.72, 95% CI 0.59 to 0.88). The risk reduction was not depen-
dent on the duration of HRT use. The decreased risk of gout in current users of
opposed oestrogens was only observed in patients without renal failure. Of in-
terest, when we stratified by arterial hypertension, another comorbidity which
has been associated with an increased risk of gout in this and other studies
(5, 6), the observed relative risk reduction was more pronounced in cases and
controls with recorded arterial hypertension. Again, no such risk reduction
was seen in users of unopposed oestrogens. When we stratified by hysterec-
tomy status, a protective effect of opposed oestrogens was observed in patients
without prior hysterectomy, while no association was observed in unopposed
oestrogen users. When we stratified opposed oestrogens by progesterone com-
ponents, only norethisterone plus oestrogen, and medroxyprogesterone plus
oestrogen were associated with a decreased risk of incident gout. Of note,
tibolone, a synthetic steroid hormone acting as selective tissue estrogenic ac-
tivity regulator acting as oestrogen receptor agonist (34), was also associated
with a decreased risk of gout. When we stratified by route of administration,
current use of oral opposed oestrogens was associated with a significantly de-
creased risk of incident gout, while transdermal patches were not associated
with an altered risk.
Taken together, our results suggest that the progesterone component in op-
posed oestrogen formulations may explain the observed relative risk decrease of
gout in association with use of opposed oestrogens, a risk reduction which was
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only observed in absence of renal failure and which was more pronounced in
the presence of diagnosed arterial hypertension, suggesting effect modification
by these parameters.
Strengths and limitations
Our large population-based study has several strengths. We were in a po-
sition to study a large number of cases with incident gout in a well-established
primary care database (23, 28-31). Furthermore, we were able to analyse
opposed and unopposed oestrogens separately and to explore the gout risk
in association with duration of HRT use and with route of administration.
We were able to run various sensitivity analyses to address potential biases.
We further adjusted our analyses for important potential confounders such
as BMI, smoking status, alcohol consumption, renal failure, hypertension and
concomitant drug therapies. Since information on diseases and drug exposure
was prospectively entered in the CPRD in the absence of any study hypothesis,
recall bias is not an issue.
Some limitations of our study have to be acknowledged. Misclassification
of some gout cases may occur, although a previous study has shown that gout
diagnoses are recorded with high validity in the CPRD (32). To minimize mis-
classification, we excluded patients with recorded diagnoses of other rheumatic
diagnoses at any time within their history, and we further excluded all patients
with less than 3 years of recorded history in the database prior to the index
date to reduce the risk of including prevalent rather than incident gout cases.
We were not in a position to assess menopause, since menopause status is
not consistently recorded by the general practitioner. However, HRT is pre-
scribed mostly in postmenopausal women for symptomatic relief, usually as
combined oestrogen plus progesterone therapy in women with an intact uterus
(21). The analysis stratified by hysterectomy status was consistent with re-
sults from the main analysis; we therefore assume that our study population
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is representative of postmenopausal women.
In addition, we were not able to adjust for all known potential risk fac-
tors for gout since, for example, dietary habits or physical activity (1, 3) are
not routinely recorded in the CPRD. However, we adjusted for BMI, a factor
that is related both to physical activity and dietary habits. Finally, we could
not address potential confounding by socioeconomic status, but we partially
controlled for this parameter by matching cases and controls on general prac-
titioner, since patients from the same neighbourhood tend to see the same
general practitioner.
Comparison with other studies
To our best knowledge the study by Hak et al. (9) is, to date, the only
one which explored the association between HRT use and the risk of incident
gout. The authors found a slightly decreased risk of gout in postmenopausal
hormone users (relative risk 0.82, 95% CI 0.70 to 0.96) compared to non-users
of HRT. However, the investigators neither reported findings on type of HRT
(opposed versus unopposed), nor data on duration or route of HRT adminis-
tration (9).
Serum uric acid levels increase in older postmenopausal women (10), and
decreased serum uric acid levels have been observed in users of HRT compared
to postmenopausal women not using HRT (10, 19, 20). In line with these ob-
servations, investigators showed that use of oestrogens and progesterone lead
to increased renal clearance of urate and therefore decreased serum urate levels
(11, 12, 20). However, the underlying causes of these age and sex differences
remained unclear, and the number of participants analysed was small (11, 12,
20).
Of interest, use of opposed oestrogens was not associated with a decreased
risk of gout in patients with renal failure in our study, i.e. in a patient sub-
group with reduced renal uric acid excretion. However, since use of unopposed
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oestrogens was not associated with an altered risk of gout in either the main or
stratified analyses, these findings do not support the hypothesis that altered
renal uric acid handling alone explains our findings. Furthermore, hyperten-
sion also had an influence on the observed risk reduction seen for opposed
oestrogens.
Conclusions
In summary, this large observational study provides evidence that current
oral use of opposed oestrogens is associated with a decreased risk of incident
gout. The risk reduction was only observed in patients with normal renal
function, and it was more pronounced in hypertensive patients. Current use
of oral unopposed oestrogens was not associated with a decreased risk of gout
in postmenopausal women. Thus, these findings provide evidence that the
reduced gout risk seen with HRT use may be related to the progesterone rather
the oestrogen component.
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Part IV
DISCUSSION, CONCLUSION, AND OUTLOOK

8. DISCUSSION
The knowledge about the pathophysiology of and risk factors for gout has
improved within the last decades. Since gout is such an ancient disease many
risk factors have been long-known and therefore accepted. However, some risk
factors have not been investigated properly in medical research and good evi-
dence has often been lacking. This thesis aimed at describing the natural his-
tory of gout and contribut evidence to certain predisposing factors such as the
use of diuretics or antidiabetic drugs, diabetes severity or diabetes duration,
and the use of hormone replacement therapy.
To conduct and understand studies and to evaluate feasibility and limi-
tations of studies based on data from the CPRD, it is crucial to know the
databases strengths and limitations. Database research is most of the times
hypothesis generating. However, hypotheses can be tested to some extent,
while no causal relationship can be proven (26).
The first part of the project described incidence rates, demographic char-
acteristics of gout patients in the UK. A second part assessed the association
of diuretic drug use as risk factors. A third part assessed the association of
antidiabetic drugs, diabetes severity, and diabetes duration as risk factors or
protective factors. Finally, a fourth part assessed the association of hormone
replacement therapy as risk factors for incident gout. The study populations
were described in terms of demographic characteristics and the prevalence of
comorbidities and comedication prior to the index date.
In the first part of the project incident gout was recorded in 18.0 cases per
10,000 PYs, has risen, especially between 1999 and 2010, and seasonal and
regional differences exist. Risk factors for incident gout included alcohol con-
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sumption, comorbidities, especially kidney failure and congestive heart failure,
and antihypertensive comedication. Gout treatment patterns remained sta-
ble over time, only colchicine use slightly increased over time. In the second
project current use of loop diuretics, thiazide diuretics, and thiazide-like di-
uretics was associated with a substantially increased risk of incident gout. In
the third project increasing glycosylated haemoglobin (A1C) levels were asso-
ciated with a markedly decreased risk of incident gout in patients with type
2 diabetes mellitus. Neither use of insulin, metformin, nor sulfonylureas was
associated with an altered risk of incident gout. In the fourth project current
use of oral opposed, but not unopposed oestrogens, was associated with a de-
creased risk of incident gout in patients without renal failure, and it was more
pronounced in patients with hypertension. The decreased gout risk associated
with hormone replacement therapy use may be related to the progesterone
rather than the oestrogen component.
The detailed evaluation and discussion of the main results of the individual
studies are presented in the discussion section of the respective studies.
8.1 Strengths and limitations of the CPRD
Data for the studies conducted for this thesis were derived from the CPRD,
one of the largest and most detailed computerised databases with longitudinal
clinical records in primary care (12). The CPRD is known for its high quality,
completeness of information, and its representativeness of the UK population.
Therefore, studies with CPRD data are representative of the general popula-
tion.
Misclassification of some gout cases may have occurred, since diagnoses
were mainly made by general practitioners, and not all by rheumatologists.
However, a previous study has shown that gout diagnoses are recorded with
high validity in the CPRD (20). However, gout diagnoses are often made based
on clinical presentation and are rarely confirmed in routine clinical practice
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by analysis of aspirated joint fluid for evidence of urate crystals. To min-
imize misclassification, in this thesis, subjects with a differential diagnosis
such as osteoarthritis, arthropathy due to hemochromatosis, septic arthritis,
or rheumatoid arthritis were excluded from the study population.
In 2012, the CPRD was linked to several datasets, such as disease reg-
istries, mortality data, in-hospital and day-care drugs, mother-child linkage,
and many more, to maximize the population coverage. This innovation pro-
vides additional opportunities for the investigation of gout, especially when
patients are referred to rheumatologists. In addition, HES data in particular
adds valuable information. Although if most information on diagnoses and
prescriptions are complete, demographic characteristics are sometimes miss-
ing. For example, one such characteristic which is important in relation to
gout is ethnicity. Different ethnicities require different correction factors to
calculate glomerular filtration rate, which is associated with an increased risk
of developing gout when reduced. For at least some patients information on
ethnicity is now available in HES data. Of note, although information on
prescriptions is complete, this does not necessarily mean that the medication
prescribed is used. Furthermore, medication administered in the hospital is
neither captured in the CPRD nor available from HES data.
In addition, information on dietary habits is unavailable at all. Especially
in a research field like gout, which is highly affected by nutrition, these data are
desired. Lack of dietary data may have introduced a certain amount of bias,
however, in order to minimize this the multivariate analyses were adjusted for
body mass index.
Furthermore, it would be very interesting within the rheumatologic research
field to study genetic association. So far such information is not available, how-
ever, mothers and child linkage in the CPRD may allow for the study of the
association with some heredity factors.
Despite these limitations, the results of this thesis remain meaningful, and
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will hopefully lead to and encourage further research on gout. The burden of
gout and its cost are immense, and even if it is has been a long known disease,
further knowledge and especially improvement of prevention, treatment, and
patient care is necessary.
8.2 Case-control versus cohort design
Cohort and case-control studies both intend to provide the same basic in-
formation, but the collection of data is from opposite directions; cohort stu-
dies recruit their population based on the presence or absence of an exposure
while case-control studies recruit their population based on the presence or
absence of an outcome (1). It is often convenient to study many different dis-
ease outcomes in relation to a given exposure in a cohort study, while with
a case-control study it is often convenient to study many different exposures
in relation to a single disease (29, 30). In addition, the cohort analysis is ap-
propriate if one wants to assess incidence rates of a given outcome in a cohort
of patients with a given exposure, while the case-control design is highly ap-
propriate if one wants to assess the relative risk of developing an outcome in
association with one or several exposures. Furthermore, case-control studies
are prone to introduce recall bias. However, CPRD data prevent this issue
since data are prospectively entered in the absence of any study hypothesis.
In some parts of this thesis, a case-control as well as a cohort analyses could
have been chosen. However, a case-control design allowed for a significantly
higher degree of adjustment for calendar time, since cases and controls had
the same index date before which all exposures of interest were measured in
the same way. Thus, the case-control design is a highly valid and efficient
study design which is – contrary to the common mainstream opinion of several
authors of articles and textbooks – at least as good as a cohort study design
in many settings.
From a methodological point of view it is not relevant whether a cohort or
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a case-control design is chosen; the crucial points are data validity, compre-
hensiveness (i.e. the quality of the database), and statistical power. There is
no reason to discount a study simply because it is a case-control study. Accor-
ding to K. Rothman (26), the author of a standard textbook in epidemiology,
a case-control design is not less valid than a cohort study. Validity issues can
affect both cohort or case-control studies, and whether the data are captured
prospectively or retrospectively. Case-control studies reach, if conducted well,
the highest standards of validity.
8.3 Confounding by indication
Confounding by indication can be encountered in pharmacoepidemiological
studies because the allocation of treatment is not randomized and the indica-
tion for treatment may be related to the risk of future health outcomes (41).
This might have been an issue in the study
”
Use of diuretics and risk of
incident gout“, since arterial hypertension, chronic kidney diseases, or con-
gestive heart failure are comorbidities associated with gouty arthritis. While
chronic kidney disease and congestive heart failure may have causally led to
hyperuricaemia due to decreased net urate secretion, no such mechanism is
known for arterial hypertension. It may very well be that hypertension was
associated with, but not responsible for the observed risk increase, and that
maybe use of diuretics was the causal factor. One possibility to address this
problem was to change the reference group to past users of the respective drug
class as opposed to never user. This may have addressed potential confound-
ing by indication to a certain degree. Another technique, would have been
to entirely leave out the never use group, but this would not have materially
affected the direct comparison of current to past use.
It is certainly possible that disease severity for these comorbidities was
somewhat different between users and non-users of various diuretics; however,
taking into account that the disease per se did not materially alter the risk
117
estimates, disease severity was unlikely responsible for the observed results.
Finally, patients with past use of diuretics do not necessarily mean milder dis-
ease severity; these patients may have had adverse drug reactions and stopped
or switched to another drug class.
8.4 Clinical gout diagnosis
A certain degree of misclassification cannot be ruled out in this thesis. A
number of 38 case patients in the study of Meier et al. (20) who validated
the gout diagnosis is rather low. However, the fact that sensitivity analyses
in confirmed and probable cases revealed very similar findings and, combined
with the observed overall acceptance rate of 90%, argues in favour of a high
number of valid gout diagnoses recorded in the CPRD. Of note, other authors
used a similar definition (7, 21, 22).
Gout diagnoses are often made on clinical grounds and are only rarely con-
firmed by evidence of urate crystals in aspirated joint fluid in routine clinical
practice. To minimize misclassification, patients with important and/or fre-
quent differential diagnoses to gout (such as osteoarthritis, rheumatoid arthri-
tis, hemochromatosis, or septic arthritis) were excluded. It has to be acknowl-
edged that other crystal arthropathies cannot always be distinguished from
gouty arthritis by clinical presentation alone, and a certain degree of misclas-
sification was likely present as in any other study of gout based on clinical
data.
Of interest, misclassification could, in theory, have distorted our findings to-
wards the observed increased risk of gout among users of various diuretic drug
classes. This could arise if the general practitioner (or the rheumatologist, if
the patient was referred) were aware of the previously reported associations
between the use of diuretics and gout leading to the introduction of a diag-
nostic bias. However, it is rather implausible that such a diagnostic bias was
responsible for the substantially increased relative risk estimates observed in
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this particular study. Furthermore, such a bias may also be present in users of
potassium-sparing agents which were not associated with an increased risk of
gout.
8.5 Exact dosage
”
Sola dosis facit venenum“ –
”
the dose alone makes the poison“, is a quote
from Paracelsus. a Renaissance physician, botanist, alchemist, astrologer, and
general occultist. Within the CPRD the prescriptions include amount of sub-
stance, number of tablets per package, date when the drug was prescribed, and
number of prescriptions. In addition, general practitioners have the possibility
to fill in the prescribed number of tablets per day in a text-field which can be
analysed too. However, not all patient records contain this detailed informa-
tion. Furthermore, for some medicaments, such as loop diuretics or insulin,
which were part of two studies in this thesis, patients adapt the dosage on their
own, e.g. loop diuretics in patients with congestive heart failure are adapted
by body weight change and insulin due to measured blood glucose levels. This
makes it difficult to evaluate the exact dosage. However, it is rather unlikely
that this information was unequally distributed between cases and controls
and therefore had an impact on results of this thesis.
Since information on number of prescriptions is available, it can be assumed
that patients who had several prescriptions of a treatment such as insulin (that
should be used permanently and regularly), in fact use the drug regularly even
if no assumption on the compliance can be made. It is rather unlikely that
someone who gets a drug will stop it and then restart it, especially for perma-
nent treatments such insulin in patients with diabetes.
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9. CONCLUSION
Based on several pharmacoepidemiological aspects addressed in this thesis,
it can be concluded that:
– Incident gout was recorded in 18.0 cases per 10,000 PYs, has risen, es-
pecially between 1999 and 2010, and seasonal and regional differences
exist. Risk factors for incident gout included alcohol consumption, co-
morbidities, especially kidney failure and congestive heart failure, and
antihypertensive comedication. Gout treatment patterns remained sta-
ble over time, only colchicine use slightly increased over time.
– Current use of loop diuretics, thiazide diuretics, and thiazide-like diuret-
ics was associated with a substantially increased risk of incident gout.
– Increasing glycosylated haemoglobin (A1C) levels were associated with
a markedly decreased risk of incident gout in patients with type 2 di-
abetes mellitus. Neither use of insulin, metformin, nor sulfonylureas is
associated with an altered risk of incident gout.
– Current use of oral opposed, but not unopposed oestrogens, was asso-
ciated with a decreased risk of incident gout in patients without renal
failure, and it was more pronounced in patients with hypertension. The
decreased gout risk associated with hormone replacement therapy use
may be related to the progesterone rather than the oestrogen compo-
nent.
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10. OUTLOOK
There are several interesting topics to be studied in association with gout
within the CPRD in near future:
– One topic that is of major interest is to provide further information about
the gender differences; currently data on demographic characteristics,
comorbidities, and comedication in women with gout are lacking.
– Data availability and quality of serum urate levels on the CPRD should
be validated.
– Since cyclosporine has been associated with an increased risk of gout
it would be interesting to study a population with previous transplan-
tation, especially with kidney transplantation, to assess the association
of different immunosuppressive drugs.
– It would be interesting to assess the association between fenofibrate,
which has been associated with a decreased risk of gout, with different
concomitant drugs and incident gout.
– It would be interesting to conduct a cohort study within all gout patients
from the CPRD to assess different outcomes of interest, such as tendon
ruptures or hypothyroidism which have been associated with an increased
risk in patients with gout.
– It would be of great interest within the rheumatologic research field to
study genetic association. So far such information is not available. How-
ever, mothers and child linkage in the CPRD may allow for the study of
the association with some heredity factors.
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